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PITUITARY ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE (PACAP) 
REGUALTES FEEDING IN THE RAT STRIATUM AND HYPOTHALAMUS.  
 
Matthew M. Hurley, B.S. 
Marquette University, 2018 
The following dissertation focuses on preclinical rodent feeding paradigms that 
were designed to examine the mechanisms by which the brain regulates caloric 
(homeostatic) and palatability (hedonic)-driven feeding. Taken together, my findings 
suggest differentially motivated feeding can, in part, signal through isolated non-
overlapping mechanisms in the brain. Furthermore, some of these mechanisms occur in 
similar neurocircuits that have been implicated in other compulsive behaviors, such as 
drug abuse.  
 
 In an effort to support the argument that binge eating disorder (BED) and 
substance abuse share similar behavioral and molecular targets, we first demonstrate that 
the development of BED in rodents is attenuated by both systemic and central 
administration of a cysteine pro-drug (N-acetylcysteine or NAC) which is a compound 
that targets the understudied glutamate system and is currently used to treat other 
disorders that have aspects of compulsion, such as trichotillomania or drug addiction 
(chapter II). Interestingly, NAC-induced hypophagia is specific to feeding stimulated by 
palatability as NAC did not produce any suppression of feeding in animals not 
maintained under a feeding paradigm that would produce binge behavior.  
 
In addition to studying differentially motivated feeding, a large component of this 
dissertation examines the mechanisms by which the neuropeptide pituitary adenylate 
cyclase-activating polypeptide (PACAP) regulates feeding in the ventromedial nucleus of 
the hypothalamus (VMN) as well as the nucleus accumbens (NAc). Our results indicate 
that PACAP microinjected into the VMN suppresses feeding elicited specifically by food 
deprivation, as PACAP did not effecting feeding elicited by palatability. Interestingly, in 
the nucleus accumbens, a brain region important for reward related activity, PACAP 
suppresses palatably-driven feeding in satiated rats, while not effecting feeding driven by 
food deprivation (chapter III). The opposing behavioral effects of PACAP on feeding 
propelled the lab to further investigate the mechanism by which PACAP was working in 
these two regions. In the VMN, we demonstrate that PACAP interacts with leptin 
signaling as acute blockade of PACAP receptors (PAC1R) in the VMN inhibits the 
behavioral and molecular actions of leptin (chapter IV). In the nucleus accumbens, 
PACAP attenuates hedonic drive in a site-specific manner and we identified PACAP 
mRNA expressing striatal afferents originating in the prefrontal cortex (chapter V), 
which is significant as obese individuals display hypoactive medial prefrontal cortex and 
stimulation of this area decreases calories consumed and body weight. Taken together, 
the opposing behavioral effects of PACAP emphasize an important point that a signaling 
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In 1998, the medical cost alone of obesity in the United States of America was 
$78.5 billion dollars annually and by 2008 this number rose to a staggering 147 billion 
annually (Finkelstein, Trogdon, Cohen, & Dietz, 2009). The most costly impact of 
obesity stems from premature death arising from co-morbid illnesses such as diabetes, 
high blood pressure, heart attack, and stroke (Allison, Fontaine, Manson, Stevens, & 
VanItallie, 1999). Currently in the United States, an estimated 30% of the adult 
population is obese and this number is only expected to rise (OECD, 2013). Taken 
together, it remains critical to continue to interrogate the mechanisms by which the 
mammalian brain regulates feeding behavior and how it contributes to the obesity 
epidemic. By better understanding the central mechanisms governing food consumption, 
there is a greater chance of identifying and developing novel therapeutic approaches to 
combat the growing obesity epidemic.  
 
Overview 
From single cell to complex multi-cell organisms, the act of seeking and ingesting 
nutrients is crucial for survival. Therefore, throughout evolution, feeding has become an 
extremely complex and protected behavior. In mammals, feeding behavior is governed 
primarily by the brain. It has been well documented that there are a number of different 




Morrison, 2008; Lenard & Berthoud, 2008; Rossi & Stuber, 2018). The wide distribution 
of brain areas and signaling molecules ensures an organism will be able to seek, consume 
and metabolize calories under a myriad of physiological and behavioral conditions. 
Evolutionarily, the diffuse complex manner by which the brain regulates feeding can 
certainly be considered an advantage, but the complexity of this behavior makes it 
difficult to identify discrete alterations to the brain that drive the pathological 
development of feeding disorders. With multiple brain sites simultaneously regulating 
feeding behavior, it becomes difficult to untangle where the site of dysregulation may 
exist in a pathological feeding state. 
 To address this challenge, the following dissertation utilizes preclinical rodent 
feeding paradigms designed to elicit intake stemming from a specific motivation or drive. 
The two motivated feeding states investigated in this thesis include caloric need or 
homeostatic hunger and feeding elicited by the palatability of the food or hedonic 
hunger. Animals that are given access to food after an extended period of food 
deprivation predictably engage in a large bout of rebound feeding due to homeostatic 
hunger or the drive to restore caloric resources. Animals given brief intermittent access to 
a palatable diet will also engage in large bouts of feeding, except this behavior can be 
driven by hedonic hunger as well as homeostatic hunger.  Identifying and understanding 
the mechanism of feeding behavior that is driven only by a single motive rather than 
multiple and simultaneous drives will allow us to identify points of vulnerability in 
feeding systems leading to pathological feeding behavior.   
 Obesity and binge eating disorder (BED), in part, result from sustained 




thought to be largely the result of dysregulated hedonic hunger, the studies described in 
chapter II utilize a limited access binge eating paradigm that produces feeding behavior 
largely thought to be elicited by hedonic hunger. Animals maintained on this well-
accepted preclinical model of BED display large bouts of feeding only for a highly 
palatable food, which emulates some symptoms observed in human BED (American 
Psychiatric, 2013). As the frequent excessive binge behavior observed in BED is often 
compared to other compulsive behaviors such as substance abuse (Johnson & Kenny, 
2010; Volkow, Wang, Tomasi & Baler, 2013), we examined whether binge eating 
behavior could be suppressed by using a compound shown to have therapeutic effects on 
other compulsive behaviors. In chapter II, we demonstrate that administration of the 
cysteine prodrug, N-acetylcysteine (NAC) both systemically and centrally curbed BED-
like feeding behavior (Hurley et al., 2016b). Interestingly, others have previously 
demonstrated the therapeutic potential of NAC in treating other compulsive behaviors 
such as substance abuse or trichotillomania (Grant, Odlaug, & Kim, 2009; McClure, 
Gipson, Malcolm, Kalivas, & Gray, 2014). These findings reinforce the idea that the 
compulsive aspect of BED, substance abuse, gambling, or alcoholism may, in part, 
involve similar maladaptive alterations to brain circuitry that governs reward related 
behaviors.  
In addition to studying the effect of NAC on preclinical rodent models, chapters 
III-V examine the mechanisms by which the neuropeptide pituitary adenylate cyclase-
activating polypeptide (PACAP) regulates feeding behavior in the rat ventromedial 
nucleus of the hypothalamus (VMN) as well as the nucleus accumbens (NAc). 




suppresses food intake, increases core body temperature and locomotor activity and 
ultimately decreases body weight (Resch, Albano, et al., 2014; Resch et al., 2011; Resch 
et al., 2013; Resch, Maunze, Phillips, & Choi, 2014). As these experiments were 
primarily conducted on animals that had ad lib access to standard rat chow, we attempted 
to explore whether PACAP induced hypophagia in the VMN was specific to homeostatic 
or hedonic hunger motivated feeding drives. In chapter III, we demonstrate that PACAP 
microinjected into the male rat VMN only suppressed feeding elicited by homeostatic 
hunger but not hedonic hunger. Interestingly, in the nucleus accumbens, a region of the 
brain important for reward processing, PACAP had no effect on homeostatic hunger but 
did induce hypophagia on hedonic-driven feeding (Hurley et al., 2016a). The distinctive 
role of PACAP in these two brain regions reinforces the need to avoid broad conclusions 
or interpretations of compounds or signaling molecules that can overtly regulate 
behaviors such as feeding. As a result, chapters IV and V are dedicated to further 
understanding the mechanisms by which PACAP signals in each of these brain regions. 
Chapter IV demonstrates that acute antagonism of endogenous PAC1R-dependent 
activity in the VMN blocks the action of leptin on both behavioral and molecular 
endpoints illustrating an important point that PACAP in the VMN does not regulate 
feeding behavior independently, but rather in conjunction with more classical metabolic, 
homeostatic signals such as leptin. Additionally, this dataset demonstrates the potential 
that central leptin resistance may not be a disruption specifically of the leptin signaling 
cascade but an integrated signaling mechanism involving PACAP actions. To further 
characterize the actions of PACAP in the accumbens, chapter V demonstrates PACAP 




palatable solution and opposes dopamine actions on palatable feeding. Animals 
pretreated with the dopamine receptor 1 agonist, SFK 81297, blocked PACAP induced 
hypophagia of palatable feeding suggesting that PACAP and dopamine may interact in 
this reward center of the brain. Thus, we show that PACAP can effect one type of feeding 
in the hypothalamus through an interaction with leptin, and regulate a different motivated 
feeding behavior in the accumbens through interactions with dopamine.  
The following introduction will include: i) a description of behavioral similarities 
between human BED and frequently used preclinical models; ii) a brief outline of human 
and rodent studies demonstrating the similarities between BED and substance abuse; iii) 
studies demonstrating the important role leptin and PACAP  play in the VMN regulation 
of energy expenditure and finally iv) a summary of the relevant preclinical studies 
examining food intake and hedonic perception in the nucleus accumbens.    
 
Preclinical rodent models of binge eating emulate different aspects of BED. 
 In a study of 1,984 obese individuals seeking weight-loss counseling, 
approximately 30% of them met the criteria for the diagnosis of BED (Spitzer et al., 
1992). Others have found similar trends (Fairburn, 2008;  Hudson, Hiripi, Pope &  
Kessler, 2007) and even demonstrated that BED is associated with severe obesity with 
BMI measurements greater than 40% (Fairburn, 2008). Currently, the DSM-5 defines 
BED as recurrent, large meals of highly palatable food that occurs without compensatory 
behavior (i.e. vomiting, laxatives, etc.) observed in other feeding disorders such as 
bulimia nervosa. Additionally, those who suffer from BED often report a loss of control 




hunger as binge episodes can occur regardless of energy state (American Psychiatric, 
2013). Thus, BED is a prominent risk factor for potential excess weight gain (Hudson et 
al., 2010). Interestingly, obese individuals diagnosed with BED display enhanced 
dopamine release in the dorsal striatum in response to a food stimulus compared to obese 
individuals not diagnosed with BED (Wang et al., 2011). Enhanced activity of the dorsal 
striatum is observed in drug addicts and is thought to be responsible for the habitual 
compulsive component of addiction (Gerdeman, Partridge, Lupica, & Lovinger, 2003). 
This demonstrates an important point that BED has a unique compulsive component 
potentially involving the reward center of the brain, in a manner that is not typical of 
most obese individuals. The following section will illustrate data from different 
preclinical rodent models that emulate certain aspects of human BED.     
The sugar addiction model 
  Compared to healthy and obese controls, BED patients most often prefer sweet 
palatable food, which are primarily composed of sugar and over refined-carbohydrates 
(Davis et al., 2008). The “sugar addiction” preclinical rodent paradigm uses intermittent 
sugar access in combination with food deprivation to generate BED-like behavior. In 
brief, this model food deprives rodents for 12 hours and then four hours into the dark 
cycle animals are given 12-hour access to a sugar solution (either 10% sucrose or 25% 
glucose) as well as a nutritionally balanced chow (Avena, Rada, & Hoebel, 2006, 2008; 
Colantuoni et al., 2001). Most notably, animals maintained on this paradigm display large 
bouts of sugar solution intake, especially during the first hour of access, which the 
experimenters define as binge behavior (Colantuoni et al., 2001). Animals maintained on 




control animals with ad lib (continuous) access to the same sugar solution and chow 
(Avena et al., 2008). Besides recurrent large meals of highly palatable food, animals 
subjected to this model display heightened states of anxiety and depressive-like 
phenotypes (Avena et al., 2008). As a result, this model additionally mirrors the 
psychiatric disorders such as increased, anxiety, depression and most notably, substance 
abuse that can be similarly observed in individuals diagnosed with BED (Grilo, White, & 
Masheb, 2009).  
Although the sugar addiction model provides several behavioral phenotypes that 
mimic aspects of human BED, it should be noted that this preclinical model of BED did 
not produce any significant differences in weight gain compared to control groups. As 
animals begin to escalate sugar intake they also self-restrict on chow resulting in no net 
change in total calories (Avena & Hoebel, 2003; Colantuoni et al., 2002). While a lack of 
weight gain in BED patients has been reported (Spitzer et al., 1993), the majority of BED 
patients do gain significantly more weight compared to obese control subjects (Ivezaj, 
Kalebjian, Grilo, & Barnes, 2014). Finally, the sugar and chow being offered 4 hours into 
the dark cycle and following a 12-hour food deprivation, suggests that although animals 
display binge behavior in the first hour they have access to the sugar solution, this 
behavior may also be motivated by homeostatic hunger in addition to hedonic hunger 
since the cumulative caloric intake is not different between the binge and control group 
suggesting homeostatic set points are still in control.  
Limited access binge model 
 Unlike the liquid diet in the sugar addiction model, the limited access model 




as an adjunct to their ad lib standard chow (Corwin et al., 1998; Dimitriou, Rice, & 
Corwin, 2000). Like the sugar addiction model, animals offered limited access to a highly 
palatable, calorie dense food display large bouts of consumption of the palatable diet, 
while self-restricting intake of the standard diet offered ad lib (Corwin et al., 1998).  This 
self-restriction of standard chow leads to a lack of weight gain, similar to what was 
reported in the sugar addiction study and is a limitation to understanding the mechanisms 
responsible for the development in BED and obesity.  In chapter II, we utilize a similar 
limited access paradigm to demonstrate that therapeutic approaches used to treat 
compulsive behaviors such as substance abuse are also effective at suppressing 
compulsive binge feeding.   
  
Compulsion in BED & substance abuse overlap: Behavioral & molecular evidence 
The maladaptive feeding behavior observed in binge eating disorder can 
culminate into a destructive state similar to drug addiction (Gearhardt, White, & Potenza, 
2011; Johnson & Kenny, 2010). As compulsive feeding behavior in BED patients is 
likely a result of excessive hedonic drive rather than unmet homeostatic needs, there is an 
overwhelming need to continue examining the parallels between these two motivations, 
in humans as well as preclinical models  (Fisher & Birch, 2002; Marcus & Kalarchian, 
2003). The following section will outline both human and rodent data and highlighting a 







     Human evidence 
In a study of 404 patients diagnosed with BED, 73.8% of patients were also 
diagnosed with at least one other psychiatric disorder in their lifetime and 24.8% of these 
individuals developed substance abuse (Grilo et al., 2009). This high rate of comorbidity 
may be due to the loss of control and compulsive aspect of both disorders, which could 
manifest through similar neuronal adaptations. There are a number of symptoms (Fig 1.1) 
such as escalation of use, loss of control, social consequences and personal distress that 
are observed in both disorders (Smith & Robbins, 2013). In addition to these symptoms, 
chronic substance abuse and BED patients also display similar cognitive deficits effecting 
executive function, inhibitory control, impulsivity, cognitive flexibility and other 
complex behaviors regulated by the frontal cortex (Aloi et al., 2015; Boeka & Lokken, 
2011; Kelley, Yeager, Pepper, & Beversdorf, 2005; Lyvers & Yakimoff, 2003).  
Figure 1.1 In humans, the symptoms associated with substance dependence appear to 




 In addition to behavioral similarities, BED patients reveal abnormalities in a 
number of well-known reward centers of the brain, which are also highly implicated in 
the development of substance abuse (Michaelides, Thanos, Volkow, & Wang, 2012). For 
example, BED patients have diminished activation of cortical regions (ventromedial 
prefrontal, inferior-frontal, insular) responsible for impulse control in tasks designed to 
test this behavior (Balodis et al., 2013). Furthermore, BED patients with hypoactive 
frontal cortices during reward processing were more likely to engage in subsequent binge 
sessions following treatment (Balodis et al., 2014). Like BED, substance abuse patients 
(Canterberry, Peltier, Brady, & Hanlon, 2016), pathological gamblers and those 
diagnosed with obsessive compulsive disorder (OCD) display diminished activation of 
frontal cortical regions, which demonstrates that the neural adaptations resulting in 
compulsion can drive a number of different disorders ranging from substance abuse and 
BED to gambling and OCD ( Choi et al., 2012).   
Besides the consistent dysfunction in cortical areas the striatum, a subcortical 
structure, is also a critical region for encoding and driving reward-related behavior 
further illustrating the similarities that occur between substance abuse and BED (Berridge 
& Kringelbach, 2015; Kim, Lee, Yun, & Kim, 2017). In humans, body weight gain is 
associated with increased striatal response to palatable food cues (Stice & Yokum, 2016) 
a brain region known to robustly respond to substances of abuse and use DA as a primary 
signal for hedonic experiences. Specifically, following chronic drug administration, 
addicts display reduction in striatal dopamine 2 (D2) receptor availability (Noble, 2000; 
Volkow et al., 1990). A similar magnitude decrease in D2 availability can also be 




addicts and BED patients demonstrate that there are a number of overlapping symptoms 
present in each disorder.  
Rodent studies  
 Animals maintained on a binge eating paradigm display several similarities to 
models of substance abuse. Behaviorally, animals offered limited access to a highly 
palatable food source display escalation behavior over time (Corwin et al., 1998), which 
is also observed in rodent cocaine self-administration models. Additionally, forced 
abstinence of the binge eating food source produces heightened states of anxiety, 
aggression and withdrawal-like symptoms, which have been observed in models of drug 
addiction (Colantuoni et al., 2002; Kantak & Miczek, 1986; Martin, Wikler, Eades, & 
Pescor, 1963; Schulteis, Yackey, Risbrough, & Koob, 1998; Way, Loh, & Shen, 1969). 
Interestingly, like humans, rodents maintained on a binge eating paradigm exhibit 
significant cognitive impairments suggesting potential prefrontal impairment (Chawla, 
Cordner, Boersma, & Moran, 2017) and similar to the cognitive deficits observed in 
rodent models of substance abuse.  In rodents, both drug and food stimuli result in 
dopamine release in the striatum (Rada, Avena, & Hoebel, 2005; Wise et al., 1995) as 
well as decreases in available D2-like receptor binding in the striatum and decreased D2 
mRNA levels in animals undergoing binge eating or substance abuse paradigms (Johnson 
& Kenny, 2010). The data presented in chapter II builds on the idea that substance 
abuse and binge eating disorder are linked as we demonstrate N-acetylcysteine, a 
cysteine prodrug used to treat some compulsive behaviors, has therapeutic effects on 





Pituitary adenylate cyclase-activating polypeptide (PACAP) 
As mentioned previously, a major component of this thesis is dedicated to 
understanding the mechanisms by which PACAP regulates feeding in the brain. PACAP 
was first isolated in ovine hypothalamic pituitary cells and was named after its ability to 
stimulate adenylate cyclase (Miyata et al., 1989). PACAP is a member of the secretin-
glucagon superfamily of peptides which consists of 9 peptides that play important roles in 
a number of peripheral and central biological processes (Arimura, 1998; Sherwood, 
Krueckl, & McRory, 2000). PACAP 
is 96% conserved over 700 million 
years of evolution, making it the 
ancestral molecule for which the other 
members of the glucagon superfamily 
were derived. The PACAP precursor, 
prepro-PACAP (Fig 1.2), undergoes 
post-translational processing resulting 
in a biologically inactive PACAP 
related-protein (PRP) or an active 
PACAP molecule such as PACAP 1-27 or PACAP 1-38 (Li, Nakayama, Shuto, 
Somogyvari-Vigh, & Arimura, 1998; Li, Shuto, Somogyvari-Vigh, & Arimura, 1999). 
Interestingly, both PACAP 1-27 and 1-38 despite being structurally different, show little 
difference biologically as PACAP 1-27 stimulates adenylate cyclase to similar levels as 
PACAP 1-38 (Miyata et al., 1990). All PACAP experiments in this dissertation use 
PACAP 1-38, since this is the predominate form of PACAP in the central nervous system 
Adapted from Dickson and Finlayson, 2009 Pharmacol Ther.  
Figure 1.2 The PACAP precursor is 176 
amino acids in length and can be processed 




(Ghatei et al., 1993; Hannibal et al., 1995). As PACAP mRNA is widely distributed 
throughout the brain, this ancient neuropeptide plays a functional role in a number of 
complex behaviors including, stress, mating, learning, memory, circadian rhythms, cell 
survival and energy homeostasis (Hammack & May, 2015; Hannibal, Georg, & 
Fahrenkrug, 2017; Hawke et al., 2009; Lee & Seo, 2014; Morley, Horowitz, Morley, & 
Flood, 1992; Roberto & Brunelli, 2000; Shintani et al., 2002). Although PACAP has a 
number of well characterized peripheral effects on insulin & adrenaline secretion, 
vasodilation, and immunosuppression (Vaudry et al., 2000), the following chapters 
exclusively examine the mechanisms by which PACAP regulates behavior centrally.       
PACAP receptors 
As PACAP is 68% homologous with vasoactive intestinal peptide (VIP), these 
two peptides signal through the same three receptors: PAC1R, VPAC1 and VPAC2. 
PACAP has much greater affinity for PAC1R compared to VIP (dissociation constant 
(KD); PACAP= 0.5nM; VIP>500 nM), whereas PACAP and VIP have similar affinities 
(dissociation constant (KD); PACAP & VIP= 1.0 nM) for the VPAC receptors (Dickson 
& Finlayson, 2009; Vaudry et al., 2000). PAC1R, VPAC1 and VPAC2 are all classified 
as a B1 subclass of G-coupled protein receptor or GPRCs that couple with Gas and 
stimulate adenylate cyclase activity. Besides pairing with Gas, the PAC1 and VPAC 
receptors also couple with Gaq and activate a wide variety of intracellular signaling 
cascades (Fig 1.3; Dickson & Finlayson, 2009). The VIP/PACAP receptors have diverse 
capabilities in their activation of second messenger systems, which may be due, in part, 
to the highly alternatively spliced PAC1 receptor (Blechman & Levkowitz, 2013; 




Eglen, 1999). A majority of PAC1R splice variants occur in the 3rd intracellular loop of 
humans, amphibians, fish and rodents that add one or two cassettes of 84 nucleotides (hip 
or hop1 variants) or 81 nucleotides (hop2 variant) or a combination of the two (Blechman 
& Levkowitz, 2013). In chapter III we demonstrate PACAP microinjected into the 
VMN and striatum produce opposing effects on feeding behavior and cell 
physiology.   
 
 
Central PACAP regulates different aspects of energy expenditure 
 Shortly after PACAP was discovered in 1989, it was demonstrated that an 
intracerebroventricular (ICV) injection of PACAP in mice strongly induced hypophagia 
(Morley et al., 1992), and was later found to produce similar hypophagic effects in gold 
fish, chicks, and rats (Matsuda et al., 2005; Mizuno et al., 1998; Tachibana et al., 2003). 
Although PACAP can signal through the three different receptors reviewed above, 
antagonizing the PAC1 receptor specifically blocks ICV-PACAP induced hypophagia 
Figure 1.3 Activation of PAC1R, VPAC1, VPAC2 can stimulate a number activation of 
secondary messenger systems. In addition to increasing cyclic AMP (cAMP), activation of 
PACAP receptors can increases phospholipase C, protein kinase C, phosphliipase D and 
ultimately lead to an increase in intracellular calcium, depending on which G proteins are 
bound.    




(Mounien et al., 2009). Interestingly, global knockout (KO) of PACAP, PAC1R or 
VPAC2 receptors results in a lean animal, which conflicts with expectations based on the 
ICV pharmacological studies (Adams et al., 2008; Asnicar et al., 2002; Jamen et al., 
2000). As PACAP is widely distributed in the brain, and throughout the body, the loss of 
PACAP or PAC1R may have variable effects on feeding behavior that is dependent on 
the specific brain region.  However, global KO of PACAP or PAC1R does result in early 
lethality, suggesting the PACAP signaling is critical to survival and healthy development 
(Gray, Cummings, Jirik, & Sherwood, 2001; Otto et al., 2004).   
 Exogenously applied PACAP is thought to produce changes in feeding behavior 
primarily through actions in the hypothalamus, which is supported by the extensive 
PAC1R expression in several hypothalamic nuclei and the abundance of PACAP protein 
in this brain region.  In fact, the concentration of PACAP in the hypothalamus is 
approximately 25 times greater than PACAP concentrations in the cerebral cortex 
(Hannibal et al., 1995; Hashimoto et al., 1996; Resch et al., 2011). Within the 
hypothalamus, immunohistochemical analyse of PACAP nerve fibers demonstrate that 
almost all nuclei within the hypothalamus receive dense PACAP innervation, primarily 
from either the paraventricular nucleus of the hypothalamus or the ventromedial nucleus 
of the hypothalamus (Hannibal, 2002; Nomura et al., 2000). Additionally, PACAP in the 
hypothalamus is responsive to energy states such that mice maintained on a calorie-dense 
diet for two months show significant increases in hypothalamic PACAP mRNA, whereas 
a 48 hour fast decreases mRNA levels (Hawke et al., 2009).  
 Besides direct effects on feeding behavior, PACAP-related manipulations also 




studies have demonstrated that ICV injections of PACAP increase core body temperature, 
oxygen consumption and locomotor activity in rodents (Hawke et al., 2009; Masuo, 
Noguchi, Morita, & Matsumoto, 1995; Pataki, Adamik, Jaszberenyi, Macsai, & Telegdy, 
2000). PACAP/PAC1R KO mice have elevated circulating levels of corticosterone, 
cholesterol, ketones, and triglycerides as well as lower than usual levels of liver 
glycogen, which contributes to undernourished pups with poor life expectancies (Gray et 
al., 2001; Otto et al., 2004). Interestingly, elevating colony room temperature greatly 
increased longevity of PACAP KO pups emphasizing an important role for PACAP in 
regulating body temperature (Gray, Yamaguchi, Vencova, & Sherwood, 2002). PACAP 
also has an important role in maintaining glucose homeostatic as PACAP, PAC1R and 
VPAC2 KO mice display impaired glucose tolerance and insulin hypersensitivity (Adams 
et al., 2008; Asnicar et al., 2002; Tomimoto et al., 2008). Thus, the diverse array of 
functions regulated by central and peripheral PACAP demonstrates that it is intimately 
tied to energy expenditure and metabolism.  Examining specific hypothalamic subgroups, 
our lab has previously demonstrated that an acute microinjection of PACAP directly into 
the ventromedial nucleus of the hypothalamus (VMN) strongly suppresses feeding, 
stimulates core body temperature, locomotor activity and ultimately decreases body 
weight (Resch et al., 2011; Resch et al., 2013; Resch, Maunze, et al., 2014). While the 
role of endogenous PACAP in a specific aspect of feeding behavior has still not been 
confirmed, blockade of PAC1R alone in the VMN during the dark cycle does not produce 
any significant alteration to feeding behavior whereas, antagonizing the PAC1R during 




PACAP’s endogenous hypophagic actions occur primarily during the light phase when 
animals do not typically eat.   
 
The VMN regulates energy state in part through the actions of PACAP & leptin. 
 The ventromedial nucleus of the hypothalamus (VMN) is located on the ventral 
surface of the brain on either side of the third ventricle (Paxinos & Watson, 2007). Over 
the years several studies have demonstrated that the VMN plays a critical role in 
maintaining a homeostatic set point for energy expenditure. For example, electrical 
stimulation of the VMN results in decreased feeding behavior in rats while ablation of the 
VMN produces an obese animal (Beltt & Keesey, 1975; Bray & York, 1979; 
Hetherington & Ranson, 1939).  The VMN contain a number of receptors known to 
regulate energy homeostasis such as the hypothalamic growth hormone secretagogue-
receptor (GHS-R), PAC1R and the long form of the leptin receptor, LepRb (Bennett et 
al., 1997; Hannibal, 2002; Hashimoto et al., 1996).  Leptin receptors are abundantly 
expressed throughout hypothalamic nuclei including the VMN (Elmquist, Bjorbaek, 
Ahima, Flier, & Saper, 1998).  
Central leptin signaling in the VMN 
 Leptin is an adipocyte-derived hormone that is secreted by fat cells and acts both 
peripherally and centrally to inhibit feeding behavior as well as regulate energy 
expenditure and autonomic homeostasis (Jequier, 2002; Rosenbaum & Leibel, 2014). As 
the production of leptin in fat cells is correlated with the size of the fat cell (Considine et 




levels that is hypothesized to lead to both peripheral and central leptin resistance 
(Adeyemi & Abdulle, 2000). In rodents, systemic administration of leptin rapidly 
decreases food intake and body weight (Campfield, Smith, Guisez, Devos, & Burn, 1995; 
Halaas et al., 1995; Pelleymounter, Cullen, Baker, et al., 1995; Stephens et al., 1995; 
Weigle et al., 1995). ICV microinjections of leptin confirm that leptin actions to suppress 
food intake and decrease body weight are centrally mediated (Schwartz et al., 1996). 
Interestingly, lesioning the VMN produces desensitization to central leptin administration 
in rats (Choi, Sparks, Clay, & Dallman, 1999) suggesting a functioning VMN is 
necessary for central leptin induced hypophagia. In situ hybridization by others and from 
our lab (Fig 4.2) demonstrate that the leptin receptor (LepRb) is expressed in the VMN 
(Elmquist et al., 1998; Mercer et al., 1996). The leptin receptor is a cytokine receptor that 
signals in the VMN through the Janus Kinase 2 (JAK2)-signaling transducer and 
activator of transcription 3 (STAT3) cascade and upon activation produces an increase in 
STAT3 phosphorylation (P-STAT3) which subsequently leads to gene expression (Jiang, 
Li, & Rui, 2008). An ICV injection of leptin directly activates cells in the arcuate, 
dorsomedial and ventromedial hypothalamic nuclei by increasing P-STAT3 
immunoreactivity (Hubschle et al., 2001).  In addition to increasing P-STAT3 levels, 
leptin signaling also stimulates immediate early gene expression of c-fos in the VMN 
further demonstrating that leptin activates hypothalamic neurons (Elmquist, Ahima, 
Maratos-Flier, Flier, & Saper, 1997), Additionally, direct microinjection of leptin into the 
VMN induces hypophagia more potently than an ICV injection (Jacob et al., 1997), 
which is consistent with previous studies demonstrating that electrical stimulation (i.e. 




amount of work has been done to characterize the mechanisms by which leptin exerts its 
hypophagic effects in the arcuate nucleus (Baver et al., 2014), less is known about 
leptin’s functions in the VMN. Interestingly, leptin and PACAP when microinjected in 
the VMN nearly identical physiological and behavioral effects.  
Evidence for PACAP and leptin interaction in the VMN 
 In addition to the dense expression of PACAP in the VMN, steroidogenic factor-1 
(SF-1) is also abundantly expressed in this nucleus (Meek et al., 2016). Targeted 
knockdown of SF-1 or leptin receptors specifically in SF-1 neurons in the VMN produce 
an obese animal (Dhillon et al., 2006; Majdic et al., 2002; Zhao et al., 2004). Thus, leptin 
mediated signaling in SF-1 neurons in the VMN is critical to maintaining energy 
expenditure. Interestingly, a recent publication demonstrated that SF-1 and PACAP 
mRNA are also co-localized in the VMN (Hawke et al., 2009). We have demonstrated 
PACAP and PAC1R are co-expressed in the VMN suggesting the possibility that 
exogenously applied PACAP is inducing hypophagic effects by activating PAC1R on 
LepRb/SF-1/PACAP/PAC1R expressing cells of the VMN (Fig 4.2).  In support, Hawke 
and colleagues demonstrate that an ICV injection of the PAC1R antagonist, PACAP 6-
38, into the third ventricle blocks ICV leptin induced suppression of food intake, 
stimulation of thermogenesis and decreased body weight (Hawke et al., 2009). The 
behavioral and physiological similarities that result from individual administration of 
either PACAP or leptin into the VMN and the evidence that PACAP 6-38 interferes with 
intraventricular administration of leptin suggests that both peptides could interact in the 




chapter IV of this dissertation evaluates to what degree leptin and PACAP interact 
in the VMN on a behavioral and molecular level.  
 
The nucleus accumbens is a critical site for the regulation of reward related behavior.   
 The nucleus accumbens, which can be anatomically and behaviorally dissociated 
into a core and shell region (Zaborszky et al., 1985), is located in the ventral 
compartment of the striatum and is a critical site for regulation of reward related 
behaviors (Berridge & Kringelbach, 2015). As the nucleus accumbens receives dense 
dopaminergic projections from the ventral tegmental area (Wise & Bozarth, 1984), the 
primary output cells of the nucleus accumbens (GABAergic medium spiny neurons or 
MSNs) can be sorted into two distinct populations based on whether they express D1-like 
or D2-like receptors as previous studies have estimated that only 5% of MSNs express 
both receptor types (Bertran-Gonzalez et al., 2008). Furthermore, MSNs can be 
distinguished based on their efferent targets as well. D1-like receptor expressing MSNs 
predominately project to the substantia nigra and ventral pallidum (Bocklisch et al., 2013; 
Kupchik et al., 2015), whereas D2-like receptor expressing MSNs largely project to the 
ventral pallidum (Wall, De La Parra, Callaway, & Kreitzer, 2013). Rewarding stimuli, 
such as food or drug, increase extracellular dopamine in the nucleus accumbens and 
promote approach behavior (Rada et al., 2005; Wise et al., 1995). As the nucleus 
accumbens receives dense glutamatergic afferents from the hippocampus, amygdala and 
prefrontal cortex (Floresco, Todd, & Grace, 2001; McFarland, Lapish, & Kalivas, 2003; 
Morgane, Galler, & Mokler, 2005; Stuber et al., 2011), dopamine concentrations in the 




these upstream structures (Surmeier, Ding, Day, Wang, & Shen, 2007). Interestingly, 
chemogenetic activation of D1 neurons in the nucleus accumbens, increases feeding 
behavior in rats, while inactivation of these neurons, attenuates feeding behavior (Zhu, 
Ottenheimer, & DiLeone, 2016). As PACAP microinjected into the nucleus 
accumbens attenuates hedonic hunger, chapter V of this dissertation includes 
preliminary studies examining whether pharmacological manipulation of D1-like 
receptors alters PACAP-induced changes palatable food intake.  
 
Inactivating caudal accumbens regulates hedonic perception & feeding behavior  
 In chapter III of this dissertation, we demonstrate that PACAP suppresses 
palatable-feeding in the nucleus accumbens by inhibiting neuronal activity. In addition to 
our work, others have demonstrated that PACAP microinjected into nucleus accumbens 
potently suppresses cocaine-primed reinstatement in rats (Hess et al, in prep), suggesting 
that PACAP actions in the accumbens broadly function to curb compulsive behaviors.  
Interestingly, pharmacological inactivation of the caudal dorsomedial nucleus 
accumbens, produced a significant suppression in feeding behavior in addition to 
stimulating defensive escape behavior (Reynolds & Berridge, 2001).  The anatomical site 
targeted by Reynolds & Berridge is immediately adjacent to sites targeted in our own 
nucleus accumbens studies. One could posit that activation of this region of the 
accumbens is necessary to encode rewarding stimuli or promote the ingestion of palatable 
food, whereas inactivation of this area may encode aversive associations. In addition, 
studies have shown that ingestion of foods high in sugar or fat produce a significant 




shell demonstrating that the nucleus accumbens core is sensitive to palatable components 
of food (Dela Cruz et al., 2015). Taste reactivity paradigms have been used to measure 
hedonic perception of a palatable tastant and is a method to quantifying “liking” (Ho & 
Berridge, 2014). Human infants, monkeys and rodents display highly conserved orofacial 
responses to tastants that can be categorized as the animal either “liking” or “disliking” a 
certain stimuli (Grill & Norgren, 1978). Interestingly, inactivation of the caudal 
accumbens, the same region that elicits hypophagia following inactivation, suppresses 
“liking” of a 1% sucrose solution, while simultaneously increasing “disliking” responses 
(Ho & Berridge, 2014). However, it is still not clear whether PACAP in the accumbens 
suppresses palatable food intake by altering the hedonic perception of the rewarding 
food. To address this gap in our understanding, chapter V of this dissertation 
examines the effect of NAc-PACAP on the hedonic perception of a 1% sucrose 
solution using the taste reactivity paradigm.  
 
System xc- implications in PACAP & the development of addictive behaviors. 
 A number of studies demonstrate compulsive drug seeking behavior, in part, is 
dependent on glutamatergic afferents from the prefrontal cortex to the nucleus accumbens 
core (Cornish & Kalivas, 2000; Di Ciano & Everitt, 2001; Park et al., 2002). Compulsive 
drug seeking behavior, followed by withdrawal from the substance of abuse, results in 
decreased extracellular glutamate levels in the nucleus accumbens (Hotsenpiller, 
Giorgetti, & Wolf, 2001; Pierce, Bell, Duffy, & Kalivas, 1996). Interestingly, restoring 
extracellular basal glutamate levels with cysteine prodrug, N-acetylcysteine (NAC), 




concentrations through activation of the astrocytic cystine-glutamate antiporter, system 
xc-, whereas antagonizing system xc- with (S)-4-carboxyphenylglycine (CPG) blocks 
NAC induced increase in extracellular glutamate concentrations (Baker et al., 2003; Ye, 
Rothstein, & Sontheimer, 1999). In brief, system xc- exchanges one molecule of 
extracellular cystine for one molecule of intracellular glutamate (Sato, Tamba, Ishii, & 
Bannai, 1999). Systemically administered NAC can deliver cysteine into the brain 
(Griffith, 1999; Meister, 1985), which can effectively drive the non-vesicular release of 
glutamate in the nucleus accumbens. Since PACAP receptors are expressed by glia 
(Ashur-Fabian, Giladi, Brenneman, & Gozes, 1997), and recent studies demonstrate 
that PACAP application directly drives the activity of system xc- (Kong et al., 2016; 
Resch, Albano, et al., 2014), chapter V conducts studies to determine if PACAP-
mediated suppression of hedonic hunger is in part dependent on system xc- in the 
accumbens.   
 
Summary  
 The following dissertation is comprised of preclinical animal paradigms designed to elicit 
specific motivated feeding states. As a number of studies suggest binge eating disorder and 
substance abuse share the element of compulsion, in chapter II we examine if a therapeutic 
approach used to treat other compulsive behaviors is effective at curbing the development of 
binge eating behavior.   
 Previously, our lab has demonstrated that PACAP microinjected into the ventromedial 
nucleus of the hypothalamus (VMN) profoundly suppresses food intake as well as induces several 




Maunze, et al., 2014). However, it was still not clear if VMN-PACAP manipulations regulate 
feeding behavior driven by a specific type motivation. Therefore, chapter III utilizes a novel 
feeding paradigm designed to separate homeostatic and hedonic hunger within the same animal to 
examine in detail the manner in which PACAP regulates feeding in the VMN. Furthermore, in 
chapter III we tested whether or not PACAP-mediated regulation of feeding behavior was 
ubiquitous in all brain structures by examining PACAP mediated regulation of feeding behavior 
in the striatum. In chapter IV, we examine the mechanism by which PACAP interacts at 
behavioral and molecular levels with leptin in the VMN, while in chapter V we study the impact 
of PACAP in the nucleus accumbens on hedonic contributions, in addition to possible interactions 
with dopamine and system xc-. Collectively, these findings demonstrate that central PACAP 
signaling regulates different aspects of feeding depending on where in the brain PACAP is acting 
and which specific motivation or drive to eat, homeostatic (i.e. leptin in the VMN) or hedonic 

















         CHAPTER II  
N-ACETYLCYSTEINE (NAC) DECREASES BINGE EATING IN A LIMITED 




Binge eating disorder (BED) is one of the most prevalent eating disorders in the 
United States and contributes to the obesity epidemic that is currently endangering the 
health of approximately 30% of all Americans (Hudson, Hiripi, Pope, & Kessler, 2007; 
OECD, 2013). Feeding behavior in BED is characterized by rapid consumption of large 
amounts of highly palatable food that occur in very short periods of time. Additionally, 
those suffering from BED often eat until feeling uncomfortably full and will consume 
food whether they feel the need to eat or not (American Psychiatric, 2013). Feeding 
stimulated by the palatability of the food source rather than the need to fill caloric stores 
is referred to as hedonic hunger (Lowe & Butryn, 2007) and in healthy, lean individuals 
hedonic hunger is experienced in moderation (i.e. dessert) with little to no negative effect. 
However, in BED patients, this type of palatability-driven hunger appears to be 
pathologically dysregulated.  
Compared to individuals with obesity, patients with BED displayed significantly 
higher levels of craving toward sweets, which was not observed in the obese population 
(White & Grilo, 2005). This was determined using the Food Craving Inventory (FCI), 
which is a self-reporting mechanism for monitoring a patient’s food craving for a 
particular food source (White, Whisenhunt, Williamson, Greenway, & Netemeyer, 2002). 
In a separate study, BED patients engaged more frequently in nocturnal feeding bouts of 




(Greeno, Wing, & Marcus, 1995).  These studies reinforce the idea that obesity and BED 
are in fact different. Obesity can manifest through a number of non-hedonic related 
endocrine diseases such as hypothyroidism and Cushing’s syndrome (Garrapa, Pantanetti, 
Arnaldi, Mantero, & Faloia, 2001; Sanyal & Raychaudhuri, 2016; Tiryakioglu et al., 
2010), whereas BED appears to manifest through specific dysregulation of the neuronal 
mechanisms governing hedonic hunger. To further emphasize this point, an fMRI study 
using a Monetary Incentive Delay Task (MIDT) as a measure of reward processing 
demonstrated that in individuals who were treated for BED but then relapsed to bingeing 
behavior showed diminished recruitment of reward related brain areas (ventral striatum, 
frontal gyrus) as compared to BED patients who were treated for BED but did not relapse 
(Balodis et al., 2014). This suggests that reward related circuitry, which is involved in the 
consumption of highly palatable foods, may be the source of dysregulation when it comes 
to binge eating disorder. This illustrates the importance to continue interrogating the 
neural underpinnings by which the brain regulates hedonic hunger in order to increase the 
likelihood of developing more effective therapeutic approaches to combat binge eating 
behavior and reduce obesity rates.  
Although drug addiction has been shown to involve abnormal glutamatergic 
signaling in the nucleus accumbens (Kalivas, LaLumiere, Knackstedt, & Shen, 2009), 
there are very few therapeutic approaches that directly target this system. One compound 
that does target the glutamate system, the cysteine prodrug N-acetylcysteine (NAC), has 
been shown to reduce many forms of compulsive behaviors ranging from addiction to 
trichotillomania (Amen et al., 2011; Grant et al., 2009). NAC works centrally by 




2014). NAC does this by increasing extracellular cystine concentrations, which drives the 
1:1 exchange of extracellular cystine for intracellular glutamate through system xc-. 
Increasing extrasynaptic glutamate tone via non-vesicular release can, in turn, modify 
glutamate release and subsequent receptor function (ie synaptic signaling) in regions 
implicated in motivated or compulsive behaviors including hedonic motivated eating 
(Bridges, Lutgen, Lobner, & Baker, 2012; Lin & Pratt, 2014). In support, system xc- has 
been shown to be an effective target to inhibit cocaine-induced behaviors and 
reinstatement in pre-clinical studies (Baker et al., 2003). Because of the compulsive 
aspect of binge eating, an overeating behavior analogous to drug abuse, we examined the 
potential for systemic or intraventricular administration of NAC to alter binge eating in 
rodents.   
To determine if NAC can effectively curb binge eating behavior, we utilized a  
pre-clinical model of binge eating in which rodents are permitted daily limited-access to a 
highly palatable food as an adjunct to their ad lib standard chow in order to recapitulate 
some of the characteristics of human binge eating disorder (Corwin et al., 1998). Animals 
maintained on this paradigm display rapid bouts of feeding specifically of palatable food 
indicating an excessive hedonic feeding drive.  
 
MATERIALS & METHODS  
Animals 
Male Sprague-Dawley rats (225-250g; 53-58 days old; Harlan; Indianapolis, IN) 
were housed individually under a 12 hour light/dark cycle (2PM: Lights OFF; 2AM: 




all experiments. Intake was monitored daily via a BioDAQ Food Intake Monitor 
(Research Diets, New Brunswick, NJ) or by pre-weighing food bins prior to and after 
experimental sessions. Body weights were also recorded daily. All procedures using 
animals were approved by the Marquette University Institutional Animal Care and Use 
Committee. 
 
Cannulation Surgery & Microinjections  
Animals were anesthetized with a ketamine/xylazine/acepromazine (77:1.5:1.5 
mg/ml/kg; i.p.) cocktail and placed in a stereotaxic apparatus. A 26 gauge unilateral guide 
cannula (Plastics One; Roanoke, VA) was placed into a lateral ventricle and secured to 
the skull via an acrylic resin. The stereotaxic coordinates were anterior/posterior, -0.8 
mm from bregma; medial/lateral, ± 1.5 mm from midline; dorsal/ventral, -3.0 mm from 
the surface of the skull, whereas the injector extended 0.5mm further beyond the tip of 
the guide cannula.  Stereotaxic coordinates were based on The Rat Brain in Stereotaxic 
Coordinates, 6th Edition (Paxinos & Watson, 2007). 
 
Limited access binge-eating model 
Animals with ad lib access to standard chow (Harlan 8604 formula; SC; 32% of 
total kcal protein, 54% of total kcal carbohydrate, 14% of total kcal fat; 3.0 kcal/g) were 
additionally allowed daily limited access (30 min/day) to a highly palatable western diet 
(WD; Research Diets; New Brunswick, NJ; 17% of total kcal protein, 43% of total kcal 
carbohydrate, 41% of total kcal fat; 4.7 kcal/g) shortly after lights out (30 minutes). 




injections of NAC were administered 30 minutes prior to gaining limited access to WD 
similar to the procedures used in previous work examining the pre-clinical therapeutic 
potential of systemic and centrally administered NAC in attenuating cocaine relapse 
behavior in rodents (Yonatan M. Kupchik et al., 2012). 
 
Chronic systemic N-acetylcysteine: Limited access binge   
Animals (n=12-17/treatment) received chronic intraperitoneal (i.p.) injections of 
either vehicle (saline) or N-acetylcysteine (60, 90 or 120 mg/kg) 30 minutes prior to 
gaining limited access (30 min/day) to a pre-weighed bin of WD for 7 days. Animals 
receiving 90 mg/kg were maintained on a binge paradigm for an additional 7 days, 
because NAC at this dose significantly suppressed western diet consumption after the 
first 7 days.  
 
Central N-acetylcysteine: Limited access binge  
After one week to recover from guide cannula surgery, animals (n=6-8/treatment) 
were placed on the limited access binge paradigm for 7 days during which NAC was 
injected into the cerebral ventricles on alternating days as to not associate the western diet 
with the central injection and to avoid producing significant cell damage due to repeated 
daily injections.  On days 1, 3, 5, and 7 animals received central infusions of NAC 
(10µg/5µl) while control animals received an equal volume of vehicle (saline); 
microinjections were administered 30 minutes prior to WD access. Animals were given 





Acute systemic N-acetylcysteine: ad lib SC 
 Animals (n=7-8/treatment) acclimated to the BioDAQ food monitoring system 
received intraperitoneal injections of vehicle (saline) at the onset of the dark cycle for one 
week to habituate the animals to the mild stresses of the injection. Following the 
habituation period, animals were either injected with vehicle or NAC (90 mg/kg; ) at the 
onset of the dark cycle and the animals’ feeding behavior were monitored 1 and 3 hours 
post injection.  
 
Acute systemic N-acetylcysteine: Limited access binge  
 Animals (n=6/treatment) were entrained for 14 days to the limited access binge 
paradigm as described above combined with a daily intraperitoneal injection of vehicle 
(saline) 30 minutes prior to gaining access to WD to habituate animals to the stresses of 
the injection. On the 15th day, all animals received an injection of NAC (90 mg/kg) 30 
minutes prior to western diet access followed by measurement of post-injection food 
intake.   
 
Conditioned Taste Aversion  
A separate group of animals were habituated to restricted water access (1HR/day) 
and systemic injections (i.p.) of saline 30 minutes prior to water access for 1 week. 
Subsequently, animals were separated into three treatment groups (n=5/group): saline, 
NAC (90 mg/kg; IP), or LiCl (2%; i.p.) and each offered two bottles containing a 0.15% 
saccharin solution for 24 hours then returned to their previous restricted water conditions. 




test with one bottle containing 0.15% saccharin solution and the other containing water 
for 1 hr.  
 
Progressive ratio  
 To introduce the testing environment, rats (n=4/treatment) were food deprived for 
24 hours and placed overnight in an operant chamber that allowed animals to press a 
lever to receive a 45 mg pellet of high fat diet (Bio Serv; Flemington, NJ). For the 
subsequent three days, non-food deprived animals received a vehicle injection (saline) 30 
minutes prior to being placed in the operant chamber for 30-minute lever access to the 
high fat diet pellets at the onset of the dark cycle. Animals were then put through two 
progressive ratio tests on separate days as described previously (Richardson & Roberts, 
1996), where the animal received vehicle prior to one session and NAC (90 mg/kg) prior 
to the other session.  
 
Statistics 
Data are presented as means ± standard error of the mean, and were analyzed 
statistically (Sigma Plot 11; SystatSoftware Inc.; San Jose, CA) by analysis of variance 
(with repeated measures when appropriate) or student’s t-test. Fischer LSD analysis was 









Animals given daily limited access to a highly palatable western diet (WD) in 
addition to ad lib standard chow (SC) display binge-like behavior (rapid consumption of 
calories) over an extended time course (Fig 2.1A). By day 14, a significantly larger 
percentage of the animal’s daily intake consists of the WD consumed during the 30 
minute period vs the 24 hour ad lib access to standard chow (Fig 2.1B;  p<0.05). 
Interestingly, animals given limited access to WD consumed significantly more calories 
compared to animals given ad lib access to SC or WD in a similar 30-minute time period 
(Fig 2.1C; p<0.05). Taken together, the rodent limited-access binge paradigm produces a 
state of rapid consumption that appears to be driven by palatability. In an effort to 
attenuate this binge eating, we administered the cysteine prodrug N-acetylcysteine (NAC) 
which effectively attenuated other compulsive behaviors such as drug seeking in humans 
(Amen et al., 2011) and drug-reinstatement in rodents (McClure et al., 2014). 
 
Figure 2.1  Limited access to Western Diet (WD) develops binge eating behavior. 
(A) Comprehensive view of Standard Chow (SC, ad libitum), WD (30 min/day) 
and cumulative food intake over a 14 day period. (B) Percent kilocalorie intake of 
WD on day 14 is significantly increased compared to SC intake. (C) Animals 
given limited access to WD will consume significantly more in a 30 minute 
period as compared to animals with ad libitum access to either SC or WD. Data 




Daily injections of NAC (60, 90 or 120 mg/kg; i.p.) 30 minutes prior to gaining 
access to the palatable meal decreased WD intake at all three doses (Fig 2.2). Although 
only animals receiving the 90 mg/kg dose displayed statistically significant suppression 
of WD consumption compared to saline injected animals (Fig 2.2B; Tx F(1,186)= 4.517, 
p=.043). As a result, the experiment using the 90 mg/kg dose was repeated and extended 
to 14 days to evaluate the efficacy of NAC under chronic conditions (Fig 2.3).  
 
 
Daily systemic injections of NAC (90 mg/kg; i.p.) or vehicle (saline) were 
administered 30 minutes prior to limited access (30 min/day) to WD as an adjunct to ad 
lib SC for 14 days. Animals treated with NAC consumed significantly less WD (Fig 
2.3A; treatment F(1,405)= 5.478; p=0.03), and significantly more SC (Fig 2.3B; 
treatment F(1,405)= 4.893; p<0.04) over the 2 week study. As expected, NAC treated 
animals displayed a significantly larger percentage of daily kilocalorie ingested from SC 
and a concomitant reduction in WD intake compared to vehicle treated rats by the 14th 
day of experimentation (Fig 2.3C; SC % intake t= 2.463, DF=27, p=0.020; WD % intake 
Figure 2.2 Dose response study of daily N-acetylcysteine (NAC) intraperitoneal 
(i.p.) administration on WD (30 min/day) binge. (A,C) NAC administered at 60 and 
120 mg/kg respectively, did not significantly attenuate WD consumption compared to 
control. (B) NAC administered at 90 mg/kg demonstrated a significant suppression of 




t= -2.463; DF=27, p=0.020).  The compensatory increase in SC consumption paired with 
the attenuation in WD consumption resulted in no significant change in total calories 
consumed or body weight gain (Fig 2.3D-E). In a separate study, NAC administered 
centrally every 48 hours (prior to WD access) at the onset of dark via intraventricular 
(ICV) injections displayed a similar suppression in the escalation of WD consumption 
over a 7 day period (Fig 2.3F; treatment X time F(6, 97)= 2.281; p=0.45).  
 
Figure 2.3 System (90mg/kg; i.p.) and central (10µg/5µl) NAC alters binge 
behavior produced by daily limited access to a palatable food. (A) NAC treated 
animals ate significantly less WD (30 min/day) compared to saline injected control 
animals. (B) Subsequently, NAC treated animals ate significantly more SC over the 
duration of the study. (C) Percent kilocalorie intake of SC on the 14th day is 
significantly higher for the NAC treated group, while WD consumption was 
significantly decreased compared to the control group. (D,E) There is no significant 
difference in cumulative food intake or body weight gained between the two 
experimental groups. (F) In a separate study, animals received infusions (NAC or 
saline; ICV) 30 minutes prior to accessing WD, central administration of NAC 
significantly suppressed WD consumption over the 7 day study. Data expressed as 




The hypophagic effects of NAC appear to 
be specific to palatable WD consumption as it did 
not significantly alter the feeding behavior of 
animals maintained on ad lib SC only (Fig 2.4A).  
Moreover, there were no delayed effects on 
standard chow consumption at the later time 
points of 6 or 24 hours after administration of 
NAC (data not shown), which indicates the 
action of systemic NAC on food intake is specific 
to palatable food binge. Additionally, a 
conditioned taste aversion study revealed that 
suppression of WD by NAC was not due to 
NAC-induced malaise, which was observed in 
LiCl treated animals (Fig 2.4B; water vs 
saccharine t= -43.717, DF=8, p<0.001).   
To determine if NAC was effective in 
acutely blocking established binge behavior, 
animals were entrained to the limited WD binge 
paradigm for 14 days and given daily injections 
of vehicle (to acclimate to the injection process) 
and then administered NAC (90 mg/kg; i.p.) on 
day 15. Interestingly, acute administration of 
Figure 2.4 Systemic 
administration of NAC 
(90mg/kg; i.p.) does not alter ad 
libitum SC consumption or 
produce any conditioned taste 
aversion. (A) Animals 
maintained on ad libitum SC 
and not subjected to a limited-
access binge paradigm show no 
changes in feeding behavior 
measured 1 and 3 hours post i.p. 
injection. (B) Saccharin 
preference ratio (%) of control 
(saline), NAC and LiCl (2% bw) 
treated animals produced only a 
significant suppression of 
saccharin consumption in the 
LiCl treated group.  Data 
expressed as mean ±  SEM. * = 





NAC did not produce any significant change in 
WD intake compared to the vehicle injection on 
day 14 (Fig 2.5). 
To better understand if NAC alters the 
reinforcing property of a high-fat diet reward, 
animals were placed in a progressive ratio 
paradigm whereby the animals could lever-press 
to receive a high-fat diet pellet.  Within-subject 
analysis revealed interesting trends in both “lever 
presses” and “rewards received” with systemic 
NAC appearing to suppress both categories, but 
neither reaching statistical significance (Fig 2.6A-
B; Lever presses paired t-test  t= 2.194, DF= 5, 
p=0.080; HFD rewards paired t-test t= 2.236; 
DF=5, p=0.076).  
 
 DISCUSSION 
Male rats provided daily limited access to a highly palatable food source display 
some of the behavioral similarities observed in human binge eating disorder. After 14 
days of this feeding schedule, animals consumed nearly 60% of their daily intake in the 
brief period (30 min) of access to the western diet (Fig 2.1B). As the DSM-5 defines 
BED as the consumption of large quantities of highly palatable food in a brief period of 
time, we believe the limited access model accurately mimics this aspect of human BED 
Figure 2.5 Systemic 
administration of NAC (90 
mg/kg) following a 14 day binge 
paradigm does not suppress WD 
consumption.  Animals were 
given saline injections (i.p.) for 
14 days while receiving limited 
access to WD (30 min/day), on 
the 15th day animals were 
injected with NAC prior to WD 





(American Psychiatric, 2013). Interestingly, studies using a similar design have reported 
that this model does not induce weight gain compared to control animals (Corwin et al., 
1998). This is likely because as the animal escalates daily intake in the western diet they 
limit intake in the SC thereby, maintaining consistent cumulative intake levels (Fig 
2.1A). We can conclude that although this feeding design produces some similarities to 
human binge eating, there are important differences, namely the lack of weight gain. 
These results strongly suggest that while this feeding paradigm does appear to engage a 
hedonic hunger drive, other motivations such as homeostatic drives to eat are still 
engaged and perhaps act to limit the ability to clearly interpret this behavioral data. 
 
 
As a number of parallels can be drawn between substance abuse and BED, we 
examined whether the cysteine prodrug N-acetylcysteine (NAC) can attenuate binge 
Figure 2.6 Acute systemic NAC (90 mg/kg; i.p.) on high fat diet progressive ratio. 
(A) NAC did not affect cumulative lever presses compared to vehicle injected data. 
(B)  Animals treated with NAC did not consume rewards differently compared to 
vehicle injected groups. Data expressed as within-subject individual data points in 





feeding behavior observed in a rodent limited-access feeding model as it has been shown 
in previous studies of compulsive behaviors in both humans and animals. Chronic 
systemic N-acetylcysteine significantly attenuated binge eating of a WD over a 14 day 
study (Fig 2.3A-C). Although chronic NAC administration did not alter total caloric 
intake or weight gain (Fig 2.4D;2.4E), systemic or central administration of NAC (Fig 
2.3F) was sufficient to reduce intake of highly caloric and palatable food without 
inducing malaise (Fig 2.4B). Additionally, NAC did not alter feeding behavior in animals 
only given ad lib SC, suggesting NAC induced hypophagia is specific to excessive 
hedonic feeding behavior (Fig 2.4A). Interestingly, acute systemic NAC was ineffective 
at blocking binge behavior in an animal already entrained to the binge paradigm (Fig 
2.5), whereas acute NAC did produce an interesting non-significant trend in high fat diet 
progressive ratio (Fig 2.6). A potential interpretation for why NAC was ineffective at 
blocking an established 14-day binge behavior may result from a well-established learned 
association of the highly palatable food source, such that a single treatment of NAC may 
be ineffective at overcoming this highly learned rewarding stimuli. All of our data related 
to this binge paradigm would suggest that NAC is only effective when administered 
across experimental days when learning or establishing the palatable nature of a food is 
developing. Future studies could examine binge-entrained animals administered daily 
NAC for at least two weeks to determine whether there is any effect of chronic NAC on 
established binge behavior.  
The selectivity of NAC to only regulate the development of binge eating behavior is 
quite notable as it suggests that system xc- activation does not impact overall caloric 




demonstrated to drive the activity of the cystine-glutamate antiporter, system xc-, 
promotes non-vesicular glutamate release and consequently impacts synaptic glutamate 
signaling, which is critical to the development and maintenance of a wide variety of 
compulsive behaviors (Baker, Xi, Shen, Swanson, & Kalivas, 2002; Kalivas, Lalumiere, 
Knackstedt, & Shen, 2009). Under conditions of long-term use of drugs of abuse there is 
a reduction in system xc- activity in the nucleus accumbens, which has been proposed to 
contribute to the pathological glutamate signaling contributing to addiction (Baker et al., 
2003).  Further illustrating the importance of glutamate signaling in compulsive 
behaviors, NAC treatment reduces cocaine-induced behaviors in animals and cravings 
and or use of cocaine and tobacco in humans (Amen et al., 2011; Baker et al., 2003; 
Knackstedt et al., 2009).  Although pursuing effective treatments for compulsive eating 
disorders will require further understanding of the neural mechanisms that underlie 
hedonic drive, the effectiveness of NAC to reduce binge eating of a highly caloric 
palatable food is consistent with its effect in studies of compulsive behaviors such as drug 
taking, hair pulling and skin picking, and suggests that system xc- is a potential 
therapeutic target for the treatment of compulsive feeding disorders (Amen et al., 2011; 












PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE 





A fundamental barrier to treating obesity is the challenge associated with 
understanding the specific origin of excessive feeding behavior. Until this knowledge is 
gained development of potential new treatments based on signaling mechanisms will be 
relegated to trial and error.  Discrete forms of obesity, binge eating, or other eating 
disorders could differentially stem from pathological changes in feeding circuitry driven 
by homeostatic needs (e.g., homeostatic hunger-driven feeding) or hedonic motivations 
for highly palatable foods (e.g., hedonic hunger-driven feeding) (Lowe & Butryn, 2007; 
Lowe & Levine, 2005).  However, isolating a specific anorexigenic substance that can 
suppress a particular feeding drive has been difficult to determine because feeding in 
many preclinical models likely involves multiple feeding drives.  This is particularly 
problematic with paradigms that compare the consumption of standard chow and highly-
palatable food in combination with food deprivation.  For example, in the limited-access 
binge model, subjects have ad lib access to standard chow in conjunction with brief 
access to a highly palatable food, which promotes binge eating (Corwin, 2004; Corwin & 
Hajnal, 2005; Czyzyk, Sahr, & Statnick, 2010).  While ad lib access to standard chow 
should limit homeostatic-driven feeding, animals show self-induced food deprivation 
with reduced consumption of the devalued standard chow (Corwin & Buda-Levin, 2004).  




evident by the observation that daily caloric intake and body weight remain stable in this 
paradigm despite the addition of the high-caloric food (Bake, Morgan, & Mercer, 2014).  
In the current studies, we modified this approach by restricting access to both diets in 
order to promote conditions whereby homeostatic-driven consumption of standard chow 
resulted in satiety prior to providing subjects access to highly palatable food.  By doing 
this, homeostatic and hedonic drives are more clearly separated, which enabled us to 
examine the cellular and molecular components of each feeding drive.   
Using this new model of binge eating, we first sought to characterize the cellular 
or regional contributions to homeostatic- and hedonic-driven feeding.  Initially, we 
examined the impact of hypothalamic ventromedial medial nuclei (VMN) activation on 
feeding primarily driven by homeostatic or hedonic feeding drives.  Although the VMN 
have historically been viewed as satiety centers regulating feeding behavior (King, 2006), 
it is unknown if the VMN-satiety signal also gates feeding stemming from other distinct 
drives (e.g., palatable-driven feeding).  In addition, we targeted a subregion of the 
nucleus accumbens (NAc), which has been principally linked to hedonic drives; the 
degree to which the NAc regulates other motivations to eat including homeostatic-based 
feeding is less well-studied (Baldo & Kelley, 2007; Baldo et al., 2013;  Johnson &  
Kenny, 2010).  Each of these experiments is important because human obesity can stem 
from either abnormal homeostatic feeding or, over consumption of highly palatable foods 
even in the absence of homeostatic need (Boggiano, 2016). Hence, these and future 
studies have the potential to identify drive-specific circuitry, a discovery that could help 




An additional objective of the current study was to examine whether a single 
anorexigenic substance could modify either the activity of NAc- and VMN-related 
circuitry through homeostatic- or hedonic-feeding drives.  Recently, we found that intra-
VMN administration of pituitary adenylate cyclase-activating polypeptide (PACAP) 
markedly suppressed feeding and reduced body weight even in fasted animals via the 
PAC1R receptor subtype (Resch et al., 2011; Resch et al., 2013).  Of the three PACAP 
receptors, PAC1R is primarily involved in the hypophagic properties of intra-VMN 
PACAP whereas the contribution of VPAC1 and VPAC2 are not (Resch et al., 2013). 
While the VMN express an abundant amount of PACAP mRNA, retrograde tracing has 
revealed numerous extra-hypothalamic efferents including PACAP containing 
projections from the medial amygdala and lateral parabrachial (Resch et al., 2013). In the 
NAc, similar retrograde studies show PACAP containing efferent projections to the NAc 
such as the medial prefrontal cortex (Fig 5.3). PACAP is a highly conserved neuropeptide 
that is often expressed in glutamatergic neurons and has been primarily implicated in 
neurohormone signaling, learning and memory, and neurodegenerative responses 
(Pellegri, Magistretti, & Martin, 1998; Zhou et al., 2002).  Thus, it represents an 
interesting molecular candidate since prior studies have shown that this neuropeptide is 
capable of activating and inhibiting ionotropic glutamate receptors (Macdonald et al., 
2005; Toda & Huganir, 2015).  In support, our lab has demonstrated that PACAP’s 
anorexic actions in the VMN likely augments glutamate signaling by potentiating NMDA 
receptors (Resch, Maunze, et al., 2014) whereas, PACAP in the NAc inhibits evoked 
firing in medium spiny neurons (Hurley et al., 2016a). Hence, the capacity for PACAP to 




anorexigenic peptide to inhibit NAc-related circuitry and suppress palatable-driven 
feeding while stimulating VMN-related circuitry to restrict homeostatic-driven feeding.   
 
MATERIALS & METHODS 
   
Animals 
Male Sprague-Dawley rats (Harlan; Indianapolis, IN) weighing 350-400 g, were 
housed individually in either a BioDAQ feeding system, a computer automated data 
acquisition system that records food intake measurements using an algorithmic load cell 
technology (Research Diets, New Brunswick, NJ) or standard hanging wire cages under a 
12:12 light/dark cycle. Feeding was measured via the BioDAQ system or by weighing 
food bins before and after experimental sessions (including spilled food). Body weights 
were collected daily. All animal procedures were approved by the Marquette University 
Institutional Animal Care and Use Committee. 
 
Diets 
We used Harlan standard chow (SC; #8604; 32% protein, 54% carbohydrate, 14% 
fat; 3.0 kcal/g) or a palatable western diet (WD; #D12079B; Research Diets; New 
Brunswick, NJ; 17% protein, 43% carbohydrate, 41% fat; 4.7 kcal/g).  When indicated, 
standard chow was flavored with either vanilla, almond (0.05% pure vanilla extract, 







Cannulation Surgery and microinjections  
Surgery: Animals were anesthetized with ketamine/xylazine/acepromazine 
(77:1.5:1.5 mg/ml/kg; i.p.).  26-gauge bilateral guide cannulae (Plastics One; Roanoke 
VA) were stereotaxically placed 2-3 mm above the ventromedial nuclei (VMN; 
anterior/posterior, −2.5 mm from bregma; medial/lateral, ± 0.6 mm from 
midline; dorsal/ventral, −6.2 mm from surface of the skull) or the nucleus accumbens 
(NAc; anterior/posterior, +1.6 mm from bregma; medial/lateral, +2.2 from midline; 
dorsal/ventral, -4.8mm from surface of the skull) and secured to the surface of the skull 
(Paxinos & Watson, 2007). Afterwards, brains were collected, immediately frozen and 
embedded in OCT for analysis of cannula placement.  30 µm thick sections were Nissl 
stained and only those with correct placements were included in the studies (Fig 5).  
Microinjections: Pituitary adenylate cyclase activating polypeptide (PACAP; 
50pmol/0.25 µl/side; California Peptide Research, Napa, CA), a-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA; 74.5ng/side; Tocris Bioscience, Minneapolis, 
MN); baclofen+muscimol (106.8ng /5.7 ng/side; Tocris Bioscience, Minneapolis, MN) or 
saline (vehicle) were microinjected into the VMN (0.25 µl/side) or NAc (0.5 µl/side) 
over a two minute period (using a syringe pump) in gently restrained awake animals 
followed by an additional minute to prevent backflow. 
 
Restricted feeding  
At the onset of dark, animals (n=12 total) were entrained (1 week/regimen) to 
various restricted feeding durations (2, 3, 4 or 6 hours/day in BioDAQ) using only SC.  




weights were recorded daily.  In addition to the restricted feeding groups, animals 
(n=6/group) fed SC and WD ad libitum served as control groups for feeding and body 
weight measurements. 
Two-meal model (M1-M2) 
Rats (n=12/group) were entrained to consume their daily SC intake in a 2-hour 
period after the onset of the dark phase (Meal 1; M1). After establishing consistent 
feeding patterns and weight gain (40-50 kcal/2hr; body weight gain 2-3 grams/day), 
animals were offered a short 15 min meal (Meal 2; M2) of either SC or WD (n=6/group) 
approximately 30 minutes following M1 for 7 days before experimentation. Food intake 
and body weight measurements were recorded in an additional group (n=6/group) of rats 
that were ad lib fed either SC or WD as control groups.  
In separate studies, animals were entrained to the two-meal model (M1-M2) for 5 
days before undergoing VMN or NAc cannulation surgery.  VMN microinjections of 
vehicle (n=9-10/group), PACAP (n=7/group), AMPA (n=6/group) or baclofen+muscimol 
(n=3/group) were separately administered approximately 30 minutes prior to either M1 or 
M2. Similarly, NAc microinjections of vehicle (n=9-10/group), PACAP (n=9/group), 
baclofen+muscimol (n=9/group) or AMPA (n=3/group) were administered approximately 
30 minutes prior to M1 or M2. 
 
Slice electrophysiology 
In collaboration with Dr. Q.S. Liu at the Medical College of Wisconsin, rats were 
anesthetized by isoflurane inhalation and decapitated.  Coronal slices (250 µm; n=6-7 




(VT1000S, Leica) at 4°C with a sucrose-based solution containing the following: 220 
mM sucrose, 25 mM NaHCO3, 2.5 mM KCl, 1.25 mM NaH2PO4, 0.5 mM CaCl2, 7 mM 
MgSO4, and 10 mM glucose. The slices were recovered in a sucrose-NaCl-based solution 
containing the following: 68 mM sucrose, 78 mM NaCl, 25 mM NaHCO3, 2.5 mM  KCl, 
1.25 mM NaH2PO4, 2 mM CaCl2, 1 mM MgCl2, and 10 mM glucose for 30 min at room 
temperature. The slices were then transferred to artificial cerebrospinal fluid (ACSF) 
containing the following: 125 mM NaCl, 2.5 mM KCl, 2.5 mM CaCl2, 1 mM MgCl2, 
1.25 mM NaH2PO4, 25 mM NaHCO3, and 10 mM glucose. The slices were maintained in 
ACSF for at least 1 hour before electrophysiology recordings.  All solutions are saturated 
with 95% O2 and 5% CO2. 
Whole-cell or cell-attached recordings were made from the VMN and NAc using 
patch-clamp amplifier Multiclamp 700B under infrared-differential interference contrast 
(DIC) microscopy. The VMN is an egg-shaped region located in the mediobasal 
hypothalamus adjacent to the third ventricle, and the NAc is an area around the optic 
nerve about 200 µm from the edge of the anterior commissure. Data acquisition was 
performed using DigiData 1440A digitizer (Molecular Devices). Glass pipettes (4-6 MΩ) 
were filled with an internal solution containing (in mM): 140 potassium gluconate, 5 
KCl, 10 HEPES, 2 MgCl2, 0.2 EGTA, 2 MgATP, 0.3 Na2GTP and 10 Na2-
phosphocreatine (pH 7.4 with KOH). Signals were filtered at 2 kHz and sampled at 10 
kHz. Spikes were driven by current injections from -60 to 300 pA. PACAP (100 nM) was 
added to the brain slices after the membrane potential was stable and a baseline 
measurement (control) of spontaneous activity and spike firing followed by application of 




µM) and GABAA receptor blocker picrotoxin (50 µM) were present throughout all 
physiological recordings. Recordings were performed at 32 ± 1°C using an automatic 
temperature controller (Warner Instrument).  
Corticosterone (B) Radioimmunoassay  
In a separate group of animals offered ad lib SC (n=12) or restricted SC access 
(2hr/day at the onset of the dark cycle; n=12) for two weeks, half were sacrificed at the 
onset of the dark cycle (prior to eating), and the remaining half sacrificed 2 hours into the 
dark cycle or after the restrict feeding session. Plasma B was measured from trunk blood 
using a radioimmunoassay (MP Biomedicals, Santa Ana, CA).  
 
Statistics  
Data are presented as means ± standard error of the mean and analyzed by 
ANOVA (with repeated measures when appropriate) or Student’s t-test. Fisher LSD 
analysis was used for post-hoc group comparisons using Sigma Plot 11 software (Systat 
Software Inc.; San Jose, CA). p<0.05 = statistical significance. 
 
RESULTS 
In order to develop a feeding paradigm that produced fully-satiated animals, we 
measured the total calories consumed during periods of 2, 3, 4 or 6 hours (HR) of 
restricted feeding in one minute bins (Fig 3.1A). Animals maintained on 6 HR daily 
access to SC ate significantly more cumulative kilocalories compared to animals 
maintained on 2, 3, or 4 HR access (Fig 3.2B; RESTRICT FED F(3,46)= 17.332, p < 




satiated and hungry again within the same restrict-fed session. This is illustrated in figure 
3.2C which demonstrates animals with only 2 hours access essentially engage in one long 
continuous acceleration to an extremely satiated state, whereas animals with 6 HR access 
eat less at the start, take a long break, and start eating again near the end of the 6 HR 
session. Taken together, with 2 HR access producing the greatest state of satiety in the 




Figure 3.1 Rodents maintained on restricted feeding schedule display large bouts of 
feeding motivated by homeostatic hunger. (A) Grams per minute intake of animals 
maintained on 2, 3, 4, or 6 hours daily access to standard chow (SC) at the onset of 
the dark cycle. (B) Animals offered 6 hours daily access consume significantly more 
cumulative kilocalories compared to animals with 2, 3 or 4 hours. (C) Comparison 
of 2HR feeding pattern versus animals given 6HR daily access. Data presented ± 




Two-meal model (M1-M2) and Restricted Feeding 
  The two-meal model tested food consumption in satiated vs. hungry rats. After 
entrainment to a 2 hour SC meal (M1), animals were offered a second meal (M2; 15 
minutes) consisting of either SC or WD (Fig 3.2A). Animals consuming WD during M2 
(SC-WD) consumed significantly more total daily calories than rats receiving SC (SC-
SC) (Fig 3.2A; DIET F(1,183)= 78.428, p<0.001; DIET X TIME F(7,183)= 13.279, 
p<0.001). Moreover, figure 3.2A shows SC-WD fed animals consumed more calories 
than animals provided SC (58.6 ± 0.5 Kcal) and WD ad libitum (74.9 ± 1.4 Kcal) 
demonstrating that 2 hour restricted feeding or SC-SC resulted in approximately 25% 
reduction in daily caloric intake compared to a SC ad lib fed animals and that SC-WD 
animals consumed more calories than ad lib WD fed rats.  By day 12, animals consumed 
as many calories from WD during the 15-min M2 as was consumed during the 2 hour M1 
(3.2B; p<0.001) and as a result gained significantly more body weight than rats receiving 
SC for M2 (Fig 3.2C; DIET X TIME; F(6,150)= 32.983; p<0.001). Notably, this increase 
was significantly greater than even ad lib WD fed rats.  A significant difference in body 
weight gain was evident by the third presentation of WD for M2 compared to the SC-SC 
group (p<0.001; Fig 3.2C).  In addition, SC-WD animals gained body weight faster than 
animals maintained on ad lib SC or WD (Fig 3.2C).  To determine if the two-meal model 
was a product of novelty, we offered SC made novel by flavoring with either vanilla or 
almond extract (or control) during M2. There were no differences in M2 intake over three 
days access to flavored SC (Fig 3.2D; SC vs. almond p=0.714; SC vs. vanilla p=0.902; 
almond vs. vanilla p=0.807), which contrasted the marked increase in palatable WD 





We and others have shown that animals entrained to 2 hours of restricted feeding 
show normal circadian rhythmicity and low basal and normal peak levels of 
corticosterone (B; < 3 µg/dl and >20 µg/dl, respectively) suggesting that they were not 
chronically stressed (Choi, Wong, Yamat, & Dallman, 1998; Krieger, 1980).  In support, 
we confirmed that circulating B levels did not differ between ad lib and 2 hour restrict 
fed animals (before and after their meal) during a period of peak B activity (Fig 3.2E; 
FEEDING REGIMEN F(1,23)= 0.017, p=0.915; FEEDING REGIMEN X TIME 
Figure 3.2 The two-meal paradigm maintained animals on restricted SC 
(standard chow) intake (M1; 2hr/day) followed by access to a second meal (M2; 
15 min/day) of SC (M1(SC)-M2(SC)) or a highly palatable diet (WD) shortly 
after M1, (M1(SC)-M2(WD)). (A) SC-WD displayed higher total food intake (FI) 
levels than SC-SC animals (and ad lib fed SC or WD animals).  (B) By day 12, 
satiated rats offered WD (SC-WD) consumed more calories than animals offered 
SC (SC-SC). (C) Animals consuming WD (SC-WD) during M2 gained 
significantly more weight than animals offered SC (SC-SC) and gained more than 
ad lib fed SC and WD animals. (D) Food intake levels of SC flavored with 
almond (Alm.) or vanilla (Van.) during M2 did no differ compared to unflavored 
SC and were significantly lower than WD. (E) Plasma B (corticosterone) levels in 
ad lib and restrict fed animals before M1 and after the onset of dark and 2 hours 
into the dark cycle (after M1). Data expressed as mean ± SEM. * = p<0.05.   
     
Ad lib SC 
Ad lib WD 
Ad lib SC 




F(1,23)= 0.302, p=0.589).  
 
VMN microinjections 
Intra-VMN PACAP (Fig 3.6A for anatomy) administered prior to M1 produced a 
significant reduction in SC consumption during M1 compared to non-injected (No INJ) 
and vehicle injected animals (Fig 3.3A; p<0.001 for both).  Intra-VMN AMPA 
administration also significantly suppressed consumption of SC during M1 (Fig 3.3A; 
AMPA vs No INJ or vehicle, p<0.001; baclofen+muscimol vs No INJ, p=0.148; vs 
vehicle, p=0.282) indicating that PACAP and AMPA produced similar behavioral actions 
in the VMN.  Surprisingly, there were no differences in the calories consumed during M2 
of either SC or WD when PACAP was administered prior to M1 (Fig 3.3A; PACAP vs. 
No INJ, p=0.624; vs. vehicle, p=0.713) or just prior to M2 (Fig 3.3B; PACAP vs. No INJ, 
p=0.613; vs. vehicle, p=0.868).  Baclofen+muscimol injections into the VMN did not 
alter feeding during either M1 or M2 suggesting that PACAP actions in the VMN are 
primarily excitatory.  Every cannula placement into the VMN was confirmed at the 
conclusion of the study resulting in a 90% accuracy rate.  
 
NAc microinjections 
NAc injections of PACAP (Fig 3.6B for anatomy), AMPA, or 
baclofen+muscimol (prior to M1) had no effect on feeding behavior during M1 (Fig 
3.4A; F(4,80)=0.463; p=0.763).  However, intra-NAc injections of PACAP and 
baclofen+muscimol significantly reduced WD intake during the subsequent 15 min M2 





baclofen+muscimol vs No INJ 
or vehicle, p<0.001). 
Similarly, PACAP and 
baclofen+muscimol 
administered just prior to M2 
also suppressed WD intake 
(Fig 3.4B; PACAP vs No INJ 
or vehicle, p<0.001; 
baclofen+muscimol vs No INJ 
or vehicle, p<0.001).  By 
contrast, AMPA 
administration into the NAc 
prior to either M1 or M2 had 
no effect on food consumption 
suggesting that PACAP 
actions in the NAc were 
inhibitory. Every cannula 
placement into the NAc was 
confirmed at the conclusion of 
the study resulting in a 90% 
accuracy rate. 
 
Figure 3.3 PACAP or AMPA microinjections 
into the hypothalamic ventromedial nuclei 
(VMN) suppressed homeostatic-induced feeding 
(meal 1; M1) without affecting palatable food 
consumption (meal 2; M2). (A) Intra-VMN 
PACAP or AMPA administered prior to M1 
significantly suppressed homeostatic-induced 
feeding of standard chow (SC) compared to 
baclofen+muscimol, vehicle (saline) and non-
injected controls, whereas there were no 
significant treatment difference in the 
consumption of SC or palatable diet (WD) 
during M2. (B) No changes in SC or WD 
consumption following microinjections 
administered just prior to M2. Data expressed as 






We determined whether 
PACAP affected action potential 
firing rates in VMN and NAc slices. 
All recordings were made in the 
presence of the glutamate receptor 
antagonist CNQX (10 µm) and the 
GABAA receptor blocker picrotoxin 
(50 µm) to block excitatory and 
inhibitory synaptic transmission.  
Cell-attached patch clamp recordings 
were made on VMN neurons, which 
displayed spontaneous action 
potential firing. Bath application of 
PACAP (100 nM) significantly 
increased the frequency of 
spontaneous action potential firing in 
VMN neurons (Fig 3.5A, t(6)=-
4.062, n=7, p<0.004, Paired t-test). 
We next examined whether PACAP 
also affected action potential firing 
in the NAc. Since medium spiny 
neurons (MSNs) in NAc slices do 
Figure 3.4 PACAP and baclofen+muscimol 
microinjections into the nucleus accumbens 
(NAc) suppressed palatable food 
consumption (meal 2; M2) without effecting 
standard chow (SC) intake (meal 1; M1). 
(A) No changes to SC intake following 
microinjections administered prior to M1 
compared to controls.  However, intra-NAc 
PACAP or baclofen+muscimol significantly 
reduced WD intake compared to AMPA, 
vehicle and non-injected controls during 
M2. (B) Similarly, WD intake was reduced 
following PACAP and baclofen+muscimol 
administration into the NAc just prior to 
M2. Data expressed as mean ± SEM. * = 





not fire spontaneous action potentials at resting membrane potential (~-80 mV), we made 
whole-cell current-clamp recordings and evoked action potential firing by injecting 
depolarizing current steps. Bath application of PACAP (100 nM) significantly decreased 
the number of spikes in responses to depolarizing current injections (Fig 3.5B, 120 pA, 
t(5)=4.828, p<0.005; 180 pA, t(5)= 4.620, p<0.006; 240 pA, t(5)=11.364, p<0.001; 300 
pA, t(5)=5.937, p<0.002, n=6). These effects were independent of excitatory and 
inhibitory synaptic inputs as these studies were conducted in the presence of both CNQX 
and picrotoxin. Thus, PACAP increased spontaneous action potential firing in the VMN 





Figure 3.5 PACAP produced opposite effects on action potential firing in the 
VMN and NAc. (A) PACAP significantly increased the frequency of spontaneous 
action potential firing in the VMN (n=7, **p<0.01 vs control). (B) PACAP 
decreased the number of spikes in the NAc in response to depolarizing current 
injections (120 pA to 300 pA, n=6, **p<0.01 vs control, *** p<0.001 vs control, 
Paired t-test).  All physiological recordings were collected in the presence of 






Obesity can stem from excessive or binge-like 
consumption of food generated by different 
homeostatic and hedonic-related drives, each of 
which may involve distinct circuitry in the brain. 
This study extends earlier findings revealing that 
PACAP administration into the hypothalamic VMN 
markedly suppressed feeding behavior (Resch et al., 
2011; Resch et al., 2013) by determining the 
capacity of this novel anorexigenic peptide to 
regulate distinct forms of eating stemming from 
homeostatic and hedonic feeding drives.  To do this, 
we developed a novel binge-eating paradigm (rapid 
consumption of a high volume of food within a short time period) that would better 
isolate distinct feeding drives. Using this paradigm, it is likely that VMN activation 
suppressed the consumption of standard chow (SC) in restrict-fed rats without altering 
palatable food intake in a satiated rat.  Inhibition of the NAc produced the opposite 
outcome in that consumption of palatable food in a satiated rat was reduced, while SC 
intake was not altered.  Interestingly, PACAP signaling in the VMN and NAc produced 
the precise changes in synaptic transmission needed to suppress each form of eating. 
Collectively, these data suggest that distinct feeding drives may involve at least partially 
non-overlapping circuitry, and that targeting PACAP signaling may be an effective 
strategy at reducing both homeostatic and hedonic-related feeding.  
Figure 3.6 Photomicrographs 
of cannula placements 
(triangles, right) and a 
representative Nissl stained 
section (30  m; left) of the 





Isolation of Homeostatic- and Hedonic-related Feeding Drives 
A challenge in the study of the neurobiology of obesity is that multiple feeding drives are 
likely simultaneously activated under most experimental conditions thereby, obfuscating 
efforts to identify the cellular or molecular basis of discrete feeding drives ( Lowe & 
Butryn, 2007; Lowe & Levine, 2005).  Many rodent models assess consumption of a 
highly-palatable food combined with some degree of food deprivation, thereby 
demonstrating the presence of multiple feeding drives even in those designed to separate 
distinct drives.  For example, in the limited-access binge model, rodents are provided ad 
lib access to SC and limited-access to palatable foods often high in both fat and sugar ( 
Corwin, 2004; Corwin & Hajnal, 2005; Czyzyk et al., 2010). While ad lib SC intake 
should mitigate homeostatic-driven feeding during the limited access to a highly 
palatable diet, rats display self-imposed deprivation evident by significantly decreased 
SC consumption.  Thus, both homeostatic- and palatability-driven feeding drives are 
likely engaged during the limited access period.   In the current approach, we limited the 
co-existence of homeostatic-driven and palatability-driven feeding drives by creating 
conditions in which restricted-feeding produces heightened homeostatic-driven feeding 
that is satiated with a low-palatable diet. It is important to note that the study of the neural 
mechanisms underlying feeding involving homeostatic- or hedonic-related drives requires 
the manipulation of these variables to understand the specific contribution of each of 
these drives.  There are three key design aspects used to create this desired experimental 
condition.  First, subjects were restrict fed for 2 hours; these conditions do not result in 
overt increases in stress hormones (Choi et al., 1998) and has previously been used by 




Mena, 2016; Denis et al., 2015; Hagan & Moss, 1997; Wei et al., 2015).  Confounding 
interactions stemming from malnourishment in these animals is extremely unlikely since 
rats with similar long-term caloric restriction paradigms (25% reduction) show improved 
life expectancy and health outcomes (Keenan et al., 1996; Keenan, Wallig, & Haschek, 
2013).  Second, SC was used as the low-palatable diet, which is illustrated in other 
studies to show diminished motivation for SC after exposure to a palatable diet (South, 
Holmes, Martire, Westbrook, & Morris, 2014).  Third, the duration of the 2-HR restricted 
feeding of SC was sufficient to produce satiety as evident by the lack of increased 
consumption when the access period was lengthened to 3 or 4 hours.  Hence, these 
conditions permit the study of the cellular or molecular basis of homeostatic-driven 
eating that culminates in a robust state of satiety.   
In the next phase of the paradigm, palatability-driven feeding was assessed by 
measuring feeding in satiated rats provided additional access (15 min) to either low- or 
high-palatable diets.  As expected, palatable food consumption significantly increased 
compared to the minimal consumption of SC.  Remarkably, the average number of 
calories consumed of a highly-palatable food by satiated rats (M2) was equivalent to the 
number of SC calories consumed during the 2-HR M1. This marked increase in the 
highly palatable food is unlikely to be due to novelty or stimulus-specific satiety since a 
similar increase was not obtained when SC was made novel with either vanilla or almond 
flavorings (Fig 3.2D).  Hence, these conditions likely permit the study of the cellular or 
molecular basis of palatable-driven feeding with limited influence from homeostatic-





VMN Gate Homeostatic But Not Hedonic-Driven Feeding  
Historically, the VMN were thought to be critical components of the brain’s 
“satiety center” (Kennedy, 1950) and later described as the inhibitory counterpart to the 
lateral hypothalamus (promoting feeding) in the dual-center hypothesis for motivated 
behavior (Stellar, 1954).  Recent studies continue to support the VMN as key sites in the 
regulation of energy homeostasis by demonstrating that specific genetic deletions in the 
VMN lead to obesity (Kim, Zhao, & Parker, 2009), altered fMRI activity is evident in the 
VMN after ingesting a glucose solution (Liu & Gold, 2003), and a positive correlation 
has been made between the degree of medial hypothalamic damage and excess weight 
gain (Pinkney, Wilding, Williams, & MacFarlane, 2002). However, an important 
outstanding question is whether the satiety signal from the VMN regulates multiple 
distinct feeding drives (e.g., homeostatic and hedonic-driven feeding). Using the two-
meal paradigm, we found that VMN activation achieved by local AMPA injections 
decreased consumption of SC in restrict-fed rats but, surprisingly, it did not alter 
palatability-driven feeding. While more work is needed to more thoroughly characterize 
this effect, these findings are consistent with the conclusion that homeostatic- and 
palatability-driven feeding involve at least partially non-overlapping circuitry.  
 
NAc Gates Palatability But Not Homeostatic-Driven Feeding  
The NAc has been strongly implicated in a wide-range of motivated behaviors, 
including palatability-driven feeding (Aragona et al., 2006; Baldo & Kelley, 2007; 
Robbins & Everitt, 1996; Wise, 1998). However, an open question is whether NAc-




studies measure intake when both homeostatic- and palatability-related drives would be 
present.  We found that local inactivation of the NAc by baclofen+muscimol reduced 
palatability-driven but not homeostatic-driven feeding.  Our finding that GABA agonists 
into the NAc did not reduce homeostatic-driven consumption of SC is consistent with 
earlier work (Stratford & Kelley, 1997).  However, we are the first to show that inhibition 
of the NAc decreased hedonic-driven feeding in rats that were accustomed to binge 
eating a palatable meal. While it is possible that regions of the NAc or ventral striatum 
not impacted by our manipulations may contribute to both forms of eating, our results, at 
a minimum, reinforce the concept that each of these feeding drives can involve unique 
circuitry.  Illustrating this point is the evidence that GABA agonist administration in 
other regions of the NAc show increased feeding behavior (Basso & Kelley, 1999).  
Thus, discretely mapping the anatomical underpinnings of various feeding drives could 
provide key insight into the etiology of eating behavior underlying distinct forms of 
obesity. For example, individuals displaying excess eating stemming from enhanced 
homeostatic-driven feeding versus those that display enhanced (or the inability to 
suppress) palatable-driven feeding may express unique molecular and cellular 
pathological changes that could be targeted by more focused therapeutic intervention.  
 
PACAP Gates Both Homeostatic- and hedonic-Driven Feeding 
In the NAc, microinjections of PACAP did not alter homeostatic feeding but 
effectively reduced consumption of a highly palatable diet. Specifically, intra-NAc 
PACAP only altered consumption of high-fat, high-carb food in a satiated rat.  The lack 




duration given that identical parameters were used in the VMN to block homeostatic 
feeding and in the NAc to block palatable feeding.  Interestingly, the activation of NAc 
efferents, all of which are GABAergic, is linked to multiple forms of motivated behavior 
including palatability-driven feeding, as described above (Aragona et al., 2006; Baldo & 
Kelley, 2007; Robbins & Everitt, 1996; Wise, 1998).  Thus, our observation that PACAP 
in the NAc mimicked the behavioral effects of GABA agonists suggests that PACAP 
likely inhibited at least some of these circuits, although as discussed below the precise 
mechanism is unknown.   
In the VMN, we found that microinjections of PACAP reduced homeostatic but 
not hedonic feeding.  In support, PACAP microinjections into the VMN decreased 
consumption only when rats displayed a pronounced homeostatic drive (e.g., following a 
22 HR fast).  Once the animal achieved a state of satiety, PACAP microinjections into the 
VMN did not alter the consumption of either standard chow or a highly palatable food 
source.  Interestingly, PACAP in the VMN mimicked the actions of AMPA microinjected 
into this structure. Given that previous studies have established the VMN as a satiety 
center of the brain in which activation of this structure reliably decreases feeding, these 
collective results suggest that both PACAP and AMPA excited VMN efferents involved 
with satiety.  While our experiments did not identify the type of cell impacted by 
PACAP, previous studies have revealed that the majority of VMN cells are glutamatergic 
(Bowers, Cullinan, & Herman, 1998; Ovesjo, Gamstedt, Collin, & Meister, 2001).  In 
support, studies have shown highly dense expression of the glutamatergic marker vGlut2 




Our finding that PACAP signaling in the VMN reduces homeostatic but not 
hedonic feeding extends existing work establishing the hypophagic and metabolic actions 
of this neuropeptide. Although PACAP signaling has been implicated in feeding behavior 
and body weight regulation for over 20 years (Chance, Thompson, Thomas, & Fischer, 
1995; Morley et al., 1992), only recent studies have begun to delineate its regional and 
mechanistic details. PACAP administration into the VMN reduces ad lib feeding without 
malaise specifically through the PAC1R receptor subtype, while also increasing 
thermogenesis and spontaneous locomotor activity (Resch et al., 2011).  Likely as a result 
of both the anorexia and the increased metabolic indices, PACAP in the VMN results in 
dramatic body weight loss even after a single acute administration (Resch et al., 2011; 
Resch et al., 2013).  Moreover, PACAP administration in the VMN increases both 
POMC mRNA expression in the arcuate nuclei and fasting glucose levels further 
illustrating a role for PACAP in the regulation of energy balance.  
Given the historical roles for the NAc in generating motivated behaviors and the 
VMN in suppressing feeding, it would seem that a molecule acting in each structure 
would need to have the remarkable capability of inhibiting the NAc while activating the 
VMN to regulate each form of eating.   While more work needs to be done to confirm 
these effects for PACAP, our data are consistent with this type of region-specific 
regulation.   In the current study, we found that bath application of PACAP to VMN 
slices increased action potential firing and that microinjections of PACAP and AMPA 
produced the same behavioral effect.  In the NAc, PACAP appears to produce the 




potentials and microinjections of PACAP into the NAc mimicked the effects of 
baclofen+muscimol on feeding.   
While the current results do not identify the molecular basis for PACAP 
mimicking GABA agonists in the NAc and AMPA in the VMN, previous work has 
shown that PACAP is able to increase or decrease the activity of glutamate ionotropic 
receptors, including NMDA (Shioda et al., 1997; Toda & Huganir, 2015; Vaudry et al., 
2009).  Lastly, previous work has also linked PACAP to other glutamatergic 
mechanisms, such as system xc- (Kong et al., 2016; Resch, Albano, et al., 2014) and 
activation of metabotropic glutamate receptors (Baker et al., 2003; Baker et al., 2002), 
which may display region-specific differences in expression (Gu et al., 2008). 
Regardless, these data show the degree to which the complexity of the glutamate network 
can differ across discrete brain regions yet be regulated by the same neuropeptide, 
potentially revealing PACAP to be a powerful regulator of caloric intake by both 
activating or inhibiting circuits associated with satiety (e.g., VMN) and appetitive (e.g., 
NAc) signals, respectively.  Future studies will be needed to explore this intriguing 
possibility. 
Collectively, these data suggest that PACAP signaling suppresses multiple 
feeding drives, which positions this novel anorexigenic peptide as an important target in 
understanding and possibly treating obesity.  Toward the latter observation, identifying 
therapeutic targets capable of modulating multiple feeding drives may be especially 
important in the treatment of obesity given the widely observed propensity for tolerance 
to anti-obesity medications to have long-term utility (Fernstrom & Choi, 2008), an effect 




may address a fundamental barrier in treating obesity by better isolating individual 
feeding drives and demonstrating the potential for PACAP signaling to regulate unique 































ANTAGONISM OF PAC1R-DEPENDENT SIGNALING IN THE VMN IS 
SUFFICENT TO BLOCK BEHAVIORAL & MOLECULAR ACTIONS OF LEPTIN.   
 
INTRODUCTION   
 In Chapter III, we demonstrate that PACAP microinjected in the VMN suppresses 
homeostatic hunger or calorically driven feeding (Hurley et al., 2016a). In the current 
chapter, we demonstrate that PACAP signaling in the VMN interacts at a behavioral and 
molecular level with the classical adipocyte-derived hormone, leptin. The data presented 
in this chapter further emphasizes the point that VMN-PACAP plays a crucial role in 
regulating homeostatic-related feeding drives by demonstrating that the central action of 
leptin, which has long been thought of as a reporter of energy state (Rosenbaum, & 
Leibel, 2014), is dependent on endogenous PACAP in the VMN.   
It has been well documented that leptin has actions both peripherally and centrally 
to regulate feeding behavior as well as energy metabolism (Pelleymounter, Cullen, Baker, 
et al., 1995; Rentsch, Levens, & Chiesi, 1995; Sidhu, Parikh, & Burman, 2000; Zhang et 
al., 1994). With leptin mRNA in fat cells correlated with cell size (Considine et al., 1995; 
Funahashi et al., 1995), excess adipose tissue in obese individuals results in chronically 
elevated circulating leptin levels which in time can lead to peripheral and central leptin 
resistance (Adeyemi & Abdulle, 2000). Moreover, this leptin-insensitivity in the 
regulation of feeding behavior has been suggested as one of the primary drivers leading 
to obesity (Berthoud, Lenard, & Shin, 2011). Taken together, understanding the 




effective therapeutic approaches to reverse leptin resistance and treat excess weight gain 
and obesity.  
 One of the main sites leptin signals in the brain is in the hypothalamus 
(Maniscalco & Rinaman, 2014), with systemic leptin administration leading to strong 
immune reactivity for phosphorylated signal transducer and activator of transcription-3 
(P-STAT3) and c-Fos protein in the arcuate nucleus as well as the ventromedial nucleus 
of the hypothalamus or VMN (Elmquist et al., 1997). P-STAT3 is the phosphorylated 
product of the janus kinase-2 (JAK2) -STAT3 cascade (Jiang et al., 2008) that is 
activated when leptin binds to the leptin receptor in these two brain regions. Although the 
mechanism by which leptin signals in the arcuate is well characterized, less is known 
about the role leptin plays in the VMN (Baver et al., 2014; Beutler et al., 2017). Previous 
studies have demonstrated that the leptin receptor (LEPR) in the VMN is expressed on 
steroidogenic factor 1 (SF-1) neurons, which is significant because specific knockdown 
of LEPR in SF-1 neurons produces an obese phenotype in rodents (Dhillon et al., 2006; 
Hawke et al., 2009). Interestingly, these SF-1 neurons also express the neuropeptide 
pituitary adenylate cyclase-activating polypeptide or PACAP. Hawke et al., suggest that 
leptin and PACAP signaling interact in the VMN as they show that acute blockade of 
PAC1R with PACAP 6-38 administered into the third ventricle, attenuated leptin induced 
suppresses of food intake, body weight and changes in thermogenesis (Hawke et al., 
2009).  
As we have previously demonstrated that PACAP microinjected into the VMN 
induces hypophagia as well as other notable changes in energy expenditure (Hurley et al., 




study was designed to evaluate the level of interaction between PACAP and leptin 
specifically in the VMN. This was achieved through a number of neuropharmacological 
experiments as well as molecular experiments using western blotting and in situ 
hybridization. Our findings demonstrate that acute blockade of PAC1R in the VMN is 
enough to disrupt VMN-leptin action behaviorally and molecularly. Future studies 
exploring central leptin resistance should therefore, take into consideration axillary 
signaling mechanisms (i.e. PACAP) that appear to gate leptin signaling in the VMN.  
 
MATERIALS & METHODS 
Animals 
Male Sprague-Dawley rats (Envigo; Madison, WI) weighing 275-300 grams upon arrival 
were housed individually in either standard tub cages or BioDAQ feeding cages 
(Research Diets; New Brunswick, NJ) and acclimated for one week to a climate 
controlled colony room under a 12:12 light-dark cycle. Animals were ad lib fed standard 
chow (Teklad rodent diet #8604; 32% protein, 54% carbohydrate, 14% fat; 3.0 kcal/g; 
Madison, Wisconsin) and body weights were measured daily. All animal procedures were 








Surgery & microinjections  
Cannulation surgery 
Animals were anesthetized with a ketamine/xylazine/acepromazine (77:1.5:1.5 mg/ml/kg; 
i.p.) cocktail and placed in a stereotaxic apparatus. 26-gauge bilateral guide cannulae 
(Plastics One; Roanoke VA) were placed 3 mm dorsal to the ventromedial nuclei (VMN) 
of the hypothalamus and secured to the surface of the skull with acrylic resin. Stereotaxic 
coordinates for VMN injections were 1) anterior/posterior, −2.5 mm from Bregma; 2) 
medial/lateral, ± 0.6 mm from midline; 3) dorsal/ventral, −6.2 mm from surface of the 
skull based on The Rat Brain (Paxinos & Watson, 2007). Following the conclusion of 
each study, animals were sacrificed and brains collected by rapid decapitation then 
sectioned and Nissl stained to determine cannula placement. Only those with correct 
placements were included in the studies. 
Telemetry probe  
Prior to VMN cannulation, some animals (n=15) were implanted intraperitoneally with a 
telemetry probe (Mini-Mitter, Sunriver, OR). Animals were allowed one week to recover 
from surgery before baseline body temperatures were monitored for one week prior to 
VMN microinjections.  
Microinjections  
PACAP (50 pmol/0.25µl per side; California Peptide Research, Napa, CA), PACAP 6-38 
(500 pmol/0.25µl per side; Anaspec, Fremont, CA), leptin (0.025 mg/0.25µl per side; 
R&D Systems, Minneapolis, MN) or saline were microinjected into the hypothalamic 




vehicle (n=4-11), leptin (n=6-10), PACAP (n=4-10), PACAP 6-38 (n=5), PACAP 6-38 
+PACAP (n=4-10) or PACAP 6-38 + leptin (n=6-12) at the onset of the dark cycle. 
Afterwards an additional minute was allotted before removing injectors to prevent 
backflow.  
 
 In situ Hybridization 
Rat brains were sectioned coronally at 12 µm and then postfixed in 4% 
paraformaldehyde, rinsed in 0.1 M PBS (pH 7.4), equilibrated in 0.1 M triethanolamine 
(pH 8.0), and acetylated in triethanolamine containing 0.25% acetic anhydride. Standard 
in vitro transcription methods were used to generate both sense and antisense riboprobes 
recognizing PAC1R, PACAP, LEPR and BDNF (Choi, Milwaukee, WI) transcripts, 
which were subsequently diluted in hybridization cocktail (Amresco, Solon, OH) with 
tRNA. Sections were hybridized overnight at 60°C with either digoxigenin (DIG) or 
fluorescein (FITC)-labeled riboprobes. After hybridization, slides were treated with 
RNase A and stringently washed in 0.3× SSC at 65°C (PAC1R/BDNF) for 30 min. Slides 
were incubated with an antibody against DIG or FITC conjugated to horseradish 
peroxidase (HRP; Roche) overnight at 4°C. Riboprobe signal was amplified using the 
TSA-Plus fluorophore system with either fluorescein or Cy3 (PerkinElmer; Waltham, 
MA). Image capture was performed using fluorescent microscopy (Axioskop-2; Zeiss, 







 Quantitative polymerase chain reaction.  
Dissected VMN tissue was frozen in liquid nitrogen and stored at -80 °C.  Total RNA 
was isolated from hypothalamic VMN punches by TRIzol extraction (Invitrogen-
ThermoFisher) and cDNA was constructed using the Reverse Transcription System 
(Promega, Madison, WI). Quantitative PCR performed using a StepOne Real-Time PCR 
System (Applied Biosystems-ThermoFisher), and PerfeCTa SYBR Green FastMix with 
ROX (QuantaBio, Beverly, MA). Quantification of mRNA expression were normalized 
to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Primers GAPDH: 5’-
CTCCCATTCTTCCACCTTTGA-3’ and 5’-ATGTAGGC CATGAGGTCCAC-3’, 
SOCS3: 5’ CCC CGC TTT GAC TGT GTA CT 3’and 5’ AAA GGA AGG TTC CGT 
CGG TG 3’, BDNF: 5’ AAA ACC ATA AGG ACG CGG ACT T 3’ and 5’ AAA GAG 
CAG AGG AGG CTC CAA 3’. 
 
 Western blotting.  
VMN tissue was collected 30 min after microinjections and flash frozen in liquid 
nitrogen and then homogenized by hand (10 strokes) in ice-cold homogenization buffer 
(300 mM sucrose, 10 mM Tris-HCl, pH 7.4, 10 mM EDTA, 10 mM EGTA) containing 
Halt protease and phosphatase inhibitor cocktail (Pierce; Rockfork, IL), followed by 3-4 
seconds of sonication. Homogenates were centrifuged at 1000 X g for 10 min at 4 °C to 
obtain the nuclear fractionation. Protein levels were measured using a bicinchoninic 
(BCA) assay (Pierce). Nuclear protein (25 µg) was run on an 8% gel by SDS-PAGE and 




odyssey blocking buffer (PBS; LI-COR Biosciences; Lincoln, NE) with 0.1% Tween-20 
and then probed with rabbit anti-phospho-STAT3 (Tyr705) antibody (Cell Signaling; 
Beverly, MA) overnight at 4°C, and then an IRDye 680 CW goat anti-rabbit secondary 
antibody (LI-COR Biosciences; Lincoln, NE) at room temperature for 1 hour. Band 
intensities for Tyr705 were visualized using the Odyssey Fc Dual Mode Imaging System. 
Blots were stripped and re-probed for total endogenous STAT3 expression using mouse 
anti-STAT3 (124H6) (Cell Signaling; Beverly, MA) and IRDye 800CW donkey anti-
mouse (LI-COR Biosciences; Lincoln, NE) antibodies. 
Statistics.   
Data are presented as means ± standard errors of the mean, and were analyzed 
statistically (Sigma Plot 11; SystatSoftware Inc.; San Jose, CA) by analysis of variance 
(with repeated measures when appropriate) or Student’s t-test. Fischer LSD analysis was 





Antagonizing VMN-PAC1R blocks leptin induced changes in feeding and energy 
expenditure. 
VMN cannulated animals received a microinjection of either saline, leptin, 
PACAP 6-38 or PACAP 6-38 + leptin at the onset of the dark cycle followed by 
measurements of feeding behavior (Fig 4.1A; left). Repeated measures two-way ANOVA 
revealed significant main effects of treatment and treatment x time (Fig 4.1A; left; 




Animals acutely injected with leptin into the VMN ate significantly less standard chow as 
compared to vehicle injected animals (Fig 4.1A; left; saline vs. leptin; p= 0.001). 
Interestingly, pretreating animals with a VMN microinjection of PACAP 6-38 prior to 
leptin injection, displayed no significant suppression of feeding behavior as compared to 
the control (Fig 4.1A; left; saline vs. PACAP 6-38 + leptin; p= 0.792). Blocking PAC1R-
dependent activity in the VMN alone produced no significant effect on feeding behavior 
(Fig 4.1A; left; saline vs. PACAP 6-38; p= 0.708). Analysis of 24-hour body weight post 
microinjection with one-way ANOVA resulted in a significant main effect of treatment 
(Fig 4.1A; right; treatment F(3,41)= 31.002; p= 0.001). With leptin treatment inducing 
profound hypophagia, leptin injected animals also lost a significant amount of weight 
compared to control treated animals (Fig 4.1A; right; saline vs. leptin; p= 0.001). 
Animals pretreated with PACAP 6-38 prior to leptin microinjection displayed similar 
weight gain to saline injected animals (Fig 4.1A; right; saline vs. PACAP 6-38 + leptin; 
p= 0.792).  
In addition to investigating VMN leptin-PACAP regulation on feeding behavior, 
in a separate study, we also analyzed regulation of thermogenesis. Analysis of core body 
temperature post-microinjection of either saline, leptin or PACAP 6-38 + leptin produced 
a significant effect of treatment over time using a two-way repeated measures ANOVA 
(Fig 4.1B; treatment x time F(38,279)=1.572, p= 0.025).  Post-hoc analysis revealed 
animals injected with leptin alone displayed a prolonged significant increase in core body 
temperature that was still significantly elevated 20 hours post injection as compared to 
vehicle (Fig 4.1B; vehicle vs. leptin, p=0.002). Interestingly, antagonizing PAC1R with 




body temperature as compared to vehicle injected animals at this same time point (Fig 
4.1B; PACAP 6-38 + leptin vs. leptin, p= 0.385). Increases in body temperature subsided 
by 30 hours post injection. Taken together, our data suggests endogenous PAC1R 
Figure 4.1 Antagonizing PAC1R in the VMN blocks VMN-leptin induced 
hypophagia, weight loss and thermogenesis. (A, left) Bilateral VMN-leptin 
(.025ug/.25µl/side) significantly suppressed feeding behavior and this suppression 
was blocked with pretreatment with PACAP 6-38 (500 pmol/.25µl/side). (A, right) A 
similar pattern of data was observed in body weight change 24HRs post 
microinjection. (B) Leptin bilaterally microinjected into the VMN stimulated 
thermogenesis significantly up to 20 hours post inject compared to vehicle and 




dependent activity in the VMN is critical for leptin-induced changes on food intake, body 
weight and thermogenesis.  
PAC1R mRNA expressing cells in the VMN also express PACAP, BDNF and LEPR.  
As Hawke and colleagues demonstrated that SF-1 neurons of the VMN also 
express PACAP (Hawke et al., 2009), we determined whether these SF-1/PACAP 
neurons also expressed the PACAP receptor PAC1R. Using double in situ hybridization 
targeting mRNA transcripts for PACAP and PAC1R, we found both signals to be 
expressed in the same cells (Fig 4.2A). Additionally, we demonstrated that PAC1R was 
Figure 4.2 In the VMN, PAC1R mRNA is co-localized with (A) PACAP, (B) BDNF, 
and (C) LEPR mRNA transcripts. VMN=ventromedial nucleus of the hypothalamus, 




also co-localized with brain derived neurotrophic factor (BDNF; Fig 4.2B) and the leptin 
receptor (LEPR; Fig 4.2C) in the VMN.  
 
Evidence for PACAP-leptin interaction at the molecular level in the VMN.  
It has been well documented that activation of the leptin receptor drives the 
JAK2-STAT3 intracellular signaling cascade (Jiang et al., 2008), which in brief, 
increases phosphorylation of P-STAT3 leading to the transcription of a number of genes, 
including suppressor of cytokine signaling-3 (SOCS3), which effectively blocks the 
phosphorylation of JAK2 and subsequently inhibits the signaling cascade. Importantly, 
previous studies have demonstrated that central and systemic leptin increases P-STAT3 
immunoreactivity in the VMN (Ladyman, Fieldwick, & Grattan, 2012). In the current 
study, we examined whether PACAP microinjection in the VMN would stimulate STAT3 
phosphorylation and gene transcription similar to those observed following leptin 
administration. PACAP stimulated phosphorylation of STAT3 in the VMN, which was 
dependent on PAC1R activation since PACAP 6-38 blocked the increase in STAT3 
phosphorylation (Fig 4.3A; treatment F(2,11)=7.733,  p=0.11; vehicle vs. PACAP 
p=0.029; PACAP 6-38 + PACAP vs PACAP p= 0.014; vehicle vs. PACAP 6-38 + 
PACAP p=0.674). In addition, leptin administration into the VMN increases mRNA 
levels of BDNF as well as suppressor of cytokine signaling-3 (SOCS3) thus, we 
examined whether PACAP would produce similar changes in gene expression and 
whether the PACAP-induced and/or leptin-induced gene expression could be blocked 
through PAC1R (Fig 4.3B). VMN cannulated animals were injected with either vehicle, 




sacrificed 3 hours post microinjected and VMN tissue was collected for qPCR analysis of 
BDNF and SOCS3 mRNA. Both leptin and PACAP treated groups displayed similar 
significant increases in BDNF mRNA expression (Fig 4.3B left; treatment F(5, 46)= 
6.800, p< 0.001; vehicle vs. PACAP p<0.001; vehicle vs. leptin p<0.001). However, 
pretreating with PACAP 6-38 prior to receiving a VMN injection blocked the effects of 
PACAP and leptin on BDNF levels (Fig 4.3B left; vehicle vs. PACAP 6-38 + PACAP, 
p=0.950; vehicle vs. PACAP 6-38 + Leptin, p=0.405). Like BDNF, a one-way ANOVA 
of SOCS3 mRNA expression revealed a significant effect of treatment (Fig 4.3B right; 
treatment F(5,45)= 2.901, p=0.025). Post-hoc analysis of PACAP or leptin treated 
animals showed significantly higher mRNA levels between PACAP and 
PACAP+PACAP 6-38 groups (p=0.006) and leptin and leptin+PACAP 6-38 groups 
(p=0.050) (Fig 4.3B right).   Antagonizing PAC1R prior to leptin or PACAP treatment 
produced similar SOCS3 mRNA levels to the vehicle treated group (Fig 4.3B right; 
vehicle vs. PACAP 6-38 + PACAP, p=0.376; vehicle vs. PACAP 6-38 + leptin, 
p=0.441).   
 
DISCUSSION  
 A number of preclinical rodent studies demonstrate that exogenous application of 
PACAP or leptin centrally or directly into the ventromedial nucleus of the hypothalamus 
(VMN) produces similar behavioral effects. Specifically, they both induce long lasting 
hypophagia, increased thermogenesis and ultimately enhanced weight loss (Jacob et al., 
1997; Morley et al., 1992; Rentsch et al., 1995; Resch et al., 2011).  The similarity in 
behavioral outcomes suggest that these two neuropeptides could use overlapping 




administration of a PAC1R antagonist has been shown to block leptin induced changes in 
food intake, body weight and thermogenesis (Hawke et al., 2009). With numerous brain 
regions showing both PAC1 and leptin receptor expression (Hashimoto et al., 1996; Scott 
et al., 2009), it is difficult to identify the specific brain region in which 
intracerebroventricular (ICV) administration of PACAP and leptin would have regulated 
these behavioral effects. The current study addresses this gap by evaluating PACAP and 
leptin interactions specifically in the VMN.  
Figure 4.3 PACAP mimics molecular actions of leptin in the VMN. (A) 30 minutes 
post microinjection PACAP treated (50pmol/.25µl/side) animals had significantly 
higher levels of P-STAT3 compared to vehicle and group pretreated with PACAP 6-
38 (500pmol/.25µl/side). (B, left) BDNF and (B, right) SOCS3 mRNA was elevated 
following microinjection of PACAP or leptin. These increases were blocked with 






 The current study’s findings are consistent with previous behavioral results 
following ICV administration of the PAC1R antagonist, PACAP 6-38, and leptin (Hawke 
et al., 2009). We confirmed that leptin alone injected into the VMN suppressed food 
intake, induce weight loss as well as stimulated thermogenesis as has been previously 
reported (Choi & Dallman, 1999; Choi et al., 1999; Dhillon et al., 2006).  However, prior 
PACAP receptor antagonism in the VMN by PACAP 6-38 prevented leptin-induced 
changes in food intake and metabolism (Fig 4.1). In the VMN, PAC1R mRNA is co-
localized with PACAP, BDNF and LEPR mRNA transcripts (Fig 4.2). Since central 
administration of PACAP and leptin produce similar behavioral and metabolic effects, we 
investigated whether PACAP in the VMN would also produce similar effects to ICV 
leptin on STAT3 phosphorylation (Hubschle et al., 2001). In line with the behavioral 
similarities between PACAP and leptin, PACAP robustly increased nuclear P-STAT3 
protein levels in the VMN, which could be blocked by PAC1R antagonism (Fig 4.3A). 
As a result of increased P-STAT3, exogenous leptin injections into VMN subsequently 
lead to increases in brain-derived neurotrophic factor (BDNF) and suppressor of cytokine 
signaling 3 (SOCS3) mRNA.  PACAP administration alone produced similar activation 
of both BDNF and SOCS3 in the VMN through the PAC1R since the PAC1R selective 
antagonist blocked increases in both mRNA levels (Fig 4.3B). 
 One possible explanation for PACAP-leptin interaction is that PAC1R dependent 
activation of a second messenger cascade in the hypothalamic VMN functions to gate 
leptin receptor function, and without PAC1R activity leptin is incapable of inducing 




hypophagia could be blocked by pretreatment with PP1, a Src kinase inhibitor (Resch, 
Maunze, et al., 2014). This key finding illustrates that PACAP’s potent action in the 
VMN on feeding behavior is dependent, in part, on Src kinase activity and suggests a 
possible intersection point leading to the phosphorylation of STAT3, independent of 
JAK2 activation (Jiang et al., 2008). This is further supported by in vitro data 
demonstrating Src kinase activation enhances leptin induced STAT3 phosphorylation 
(Jiang et al., 2008). Future studies will need to be conducted to determine if PACAP or 
leptin induced P-STAT3 and associated mRNA changes are dependent on the Src kinase 
activity.  
Our findings also demonstrate that BDNF in the VMN could be positioned as a 
common downstream effector through which PACAP and leptin regulate energy 
expenditure. VMN BDNF levels are extremely sensitive to energy state and VMN-BDNF 
function is required for leptin induced hypophagia (Conner, Lauterborn, Yan, Gall, & 
Varon, 1997; Liao et al., 2012; Xu et al., 2003). Similar to leptin and PACAP, systemic 
and direct VMN administration of BDNF strongly induces hypophagia (Pelleymounter, 
Cullen, & Wellman, 1995; Wang, Bomberg, Billington,  Levine, & Kotz, 2010), whereas 
knockdown of BDNF globally or specifically in the VMN produces hyperphagia and 
obesity (Lyons et al., 1999; Mou et al., 2015; Unger, Calderon, Bradley, Sena-Esteves, & 
Rios, 2007). Future studies will need to assess if PACAP-induced behavioral and 
molecular changes are similarly dependent on BDNF signaling.  
 In conclusion, our findings confirm that central PACAP and leptin interaction is 
observed at the level of the hypothalamic VMN.  Leptin resistance is often thought of as 




signaling cascade involving a different neuropeptide (i.e. PACAP) may also be essential 
for VMN-leptin behavioral and molecular actions. Continued interrogation of the 
mechanisms by which leptin signals may lead to novel insights on central leptin 



























      CHAPTER V 
PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE 
(PACAP) ATTENUATES HEDONIC DRIVE IN THE ACCUMBENS.  
 
INTRODUCTION 
Unfortunately, the development of effective therapeutic approaches to treat 
obesity has remained stagnant due, in part, to the overwhelming complexity of an energy 
homeostasis system that regulates vastly diverse brain processes ranging from fat 
metabolism to hedonic drive (Ahima & Antwi; Kelley, 2004; Matafome & Seica, 2017; 
Saper, Chou, & Elmquist, 2002). In the previous chapter, we provide evidence that a 
component of the PACAP system regulates homeostatic hunger, in part, through 
behavioral and molecular interactions with the homeostatic hormone leptin in the VMN. 
In the current chapter we demonstrate that PACAP microinjected into the nucleus 
accumbens (Fig 5.2), and not the VMN (Fig 5.1), regulates the hedonic perception of a 
highly palatable 1% sucrose solution (Hurley et al., in revision). This demonstrates that 
PACAP signaling regulates a different aspect of motivated feeding behavior that is tied to 
hedonics rather than homeostasis.  
There are clear psychological distinctions between ‘wanting’ and ‘liking’. First, 
‘wanting’ or incentive salience (Berridge & Robinson, 1998; Everitt & Robbins, 2005; 
Salamone & Correa, 2002), is the phenomena where cues (i.e. sight, smell, hearing, taste, 
etc.), which are associated with specific rewards, can trigger activity in the brain’s reward 
circuitry in way that increases craving or wanting of a particular reward associated with a 
cue. In rodents ‘wanting’ is studied through the use of progressive ratio paradigms, which 




particular reward (Berthoud, Zheng, & Shin, 2012).  On the other hand, ‘liking’ is 
specifically the hedonic impact of a reward, which can be interpreted as how much the 
animal enjoyed a reward (Berridge, 2009). It is important to note that ‘wanting’ and 
‘liking’ work in tandem to regulate motivated behavior but are different in that wanting is 
the act of seeking or craving a reward, whereas ‘liking’ is purely the rewarding 
experience of ingesting the reward. For example, the hedonic impact of a reward will, in 
part, determine how much ‘wanting’ behavior is displayed when cues associated with the 
reward is presented (Reilly, 1999; Yoneda et al., 2007). To distinguish hedonic impact, 
‘liking’ and ‘disliking’ can be experimentally quantified using the well-accepted taste 
reactivity behavioral paradigm, first outlined by Grill and Norgren (Grill & Norgren, 
1978). In rodents, experimenters can deliver a sweet or aversive tastant through an 
intraoral catheter, directly or involuntarily into the animal’s mouth. The method of tastant 
delivery is important because there is no aspect of ‘wanting’ or goal-directed action when 
using this experimental design. In brief, infusion of a solution into a rodent’s mouth will 
produce a diverse set of orofacial responses involving the mouth, tongue and paws 
indicating whether the animal likes or dislikes a particular stimulus (Berridge, 2000). 
Another advantage of using this rodent model is that these orofacial reflexes are also 
observed in humans as well as nonhuman primates, which speaks to the conserved 
evolutionary importance of these hedonic reflexes (Steiner, Glaser, Hawilo, & Berridge, 
2001).  
We hypothesize that PACAP microinjected into the nucleus accumbens (NAc) 
regulates hedonic hunger (Hurley et al., 2016a) by decreasing the hedonic perception of 




PACAP microinjected into the VMN or NAc on hedonic processing using a taste 
reactivity paradigm. Our results not only support a selective role for PACAP signaling in 
the NAc to alter hedonic perception but that there is also a rostral-caudal gradient for the 
efficacy of PACAP within the intra-NAc core.   
In addition to examining the impact of PACAP on the hedonic encoding of a 
rewarding stimuli, it was also pertinent to determine potential afferent projections  
responsible for the effect of PACAP on palatability in the nucleus accumbens. Through 
the combined use of retrograde tracing (cholera toxin subunit-b) and in situ hybridization, 
we identified PACAP mRNA expressing cells in the prelimbic cortex (PLC) projecting to 
the nucleus accumbens core (Fig 5.3). This is significant because previous studies have 
demonstrated stimulation of the PLC in rats decreases binge eating (Sarica et al., 2018), 
while pharmacological inactivation of the PLC specifically increases binge eating in 
rodents  ( Corwin et al., 2016). In line with these findings, a study performing 
transcranial stimulation of the prefrontal cortices in obese individuals led to a significant 
reduction in food intake and increases in weight loss (Gluck et al., 2015).  Finally, as 
previously stated, binge eating rodents display diminished performance in tasks designed 
to test prefrontal functionality, which could suggest prefrontal dysregulation or 
hypofrontality may contribute to the development of binge eating behavior (Chawla et al., 
2017). The use of in situ hybridization combined with retrograde tracing to identify 
afferents also confirmed the presence of the PAC1 receptor in the accumbens (5.4). 
Additional studies will need to examine whether other classic accumbens circuits 




The nucleus accumbens is a critical center for the regulation of reward related 
behaviors because it is densely innervated by dopaminergic afferents arising from the 
ventral tegmental area (Wise & Bozarth, 1987). The primary projection neurons in the 
nucleus accumbens are GABAergic medium spiny neurons (MSN), which can be broadly 
divided into two cell types: cells expressing D1-like receptors or cells expressing D2-like 
receptors.  Only 5% of the MSN projections express D1-like and D2-like receptors 
(Bertran-Gonzalez et al., 2008).  When an animal experiences a sweet tastant or ingests a 
high fat or sugar solution dopamine levels significantly increase in the nucleus 
accumbens, which leads to the subsequent activation of the two different subtypes of 
dopamine receptors (Avena et al., 2006; Hajnal, Smith, & Norgren, 2004; Liang, Hajnal, 
& Norgren, 2006). With D1-like receptors coupled to Gs and D2 like-receptors coupled 
to Gi, dopamine release into the accumbens following a reward (i.e. palatable food) 
increases excitability in D1 containing cells while decreasing the excitability of D2 
expressing cells (Missale, Nash, Robinson, Jaber, & Caron, 1998; Neve, Seamans, & 
Trantham-Davidson, 2004). Thus conclusions have been drawn that D1-like cells are 
responsible for encoding reward and drive approach behavior, whereas D2-like cells are 
responsible for encoding aversion and avoidance behavior (Soares-Cunha, Coimbra, 
Sousa, & Rodrigues, 2016). In support of this, in vivo electrophysiology recordings in the 
posterior nucleus accumbens core of a rodent ingesting a sucrose solution results in 
decreased firing in some cells, whereas other populations of cells increase their firing 
(Krause, German, Taha, & Fields, 2010). Interestingly, a separate study demonstrated 
that rodents ingesting a high glucose or high fat solution produced immediate early gene 




Pharmacological studies have demonstrated that blockade of either dopamine receptor 
cell populations in the core or shell of the nucleus accumbens had no effect on 
homeostatic hunger-based feeding (Baldo, Sadeghian, Basso, & Kelley, 2002). Although 
more sophisticated chemogenetic approaches demonstrated that activation of D1 neurons 
in the accumbens increased feeding behavior, whereas inhibition of these neurons 
decreased feeding behavior (Zhu et al., 2016). Excessive stimulus-induced dopamine 
release can lead to changes by which the nucleus accumbens senses dopamine. Studies 
have found D2 mRNA is decreased and D1 mRNA is increased in rodent models of binge 
eating disorder (Colantuoni et al., 2001; Johnson & Kenny, 2010). Interestingly, obese 
individuals with BED have increased dopamine release in the striatum following food 
stimulus compared to obese individuals without BED (Wang et al., 2011). This may 
explain why obese individuals self-report higher levels of pleasure and display stronger 
reinforcement for specifically high fat and/or high sugar foods, compared to lean controls 
(Rissanen et al., 2002; Saelens & Epstein, 1996). As PACAP inhibits MSN’s as well as 
suppresses palatable food intake when injected into the nucleus accumbens core (Hurley 
et al., 2016a), we hypothesize that PACAP dampens palatable food-induced activation of 
D1 cells and subsequently decrease the hedonic impact of the rewarding stimulus and 
drive to pursue palatable rewards. To test this, we entrained nucleus accumbens 
cannulated animals to the two-meal binge paradigm and pretreated them with a D1 
agonist immediately prior to a PACAP microinjection (Fig 5.5). Our findings presented 
in this chapter suggest that in the nucleus accumbens PACAP and dopamine do, indeed, 




Besides dopamine, findings in this chapter suggesting PACAP in the nucleus 
accumbens also functions through the glial cystine-glutamate antiporter, system xc- (Fig 
5.6). System xc- is a heterodimer that is attached by a disulfide bond (Bridges, Natale, & 
Patel, 2012) and consists of a 4F2 heavy chain and the xCT light chain, which is the 
unique functional component of the transporter.   System xc- exchanges extracellular 
cystine for intracellular glutamate at a 1:1 ratio (Sato et al., 1999). Recently, Kong and 
colleagues demonstrated that PACAP in vitro increases cysteine uptake only in cortical 
glial cells and not pure neuronal cultures and that this effect could be blocked by 
application of the system xc- antagonist, sulfasalazine, indicating glia are the primary cell 
type impacted by PACAP facilitated system xc- activity (Kong et al., 2016). PACAP-
induced activity of system xc- on astrocytes leads to increases in non-vesicular glutamate 
release through system xc-. This link between system xc- and PACAP is exciting because 
system xc- activity is heavily implicated in the generation of compulsive behavior in drug 
addiction models (Baker et al., 2003). To determine if system xc- was necessary for 
PACAP-induced hypophagia in the nucleus accumbens core, we entrained nucleus 
accumbens cannulated rats to the two-meal paradigm that had a mutation in the gene 
responsible for system xc- rendering animals without a functional cystine-glutamate anti-
porter. Our results suggest systemic xc- is necessary for normal PACAP mediated 









MATERIALS & METHODS 
 
Animals.  
Male Sprague-Dawley rats (Envigo; Indianapolis, IN) weighing between 250-275 
grams or system xc- mutated rats (see details below), were housed individually in 
standard tub cages or wire bottom hanging cages in a climate-controlled colony room 
under a 12:12 light/dark cycle. Animals had ad lib access to standard chow (Harlan Diet 
#8604) throughout the duration of the study unless placed in the two-meal binge 
paradigm. Additionally, food intake and body weight were recorded daily. All animal 
procedures were approved by the Marquette University Institutional Animal Care and 
Use Committee. 
 
System xc- mutated rats. 
 The laboratory of Dr. Aron Guerts from the Medical College of Wisconsin used 
Zinc-finger nucleases (ZFNs) technology to target the second exon of the Slc7a11 gene in 
rats (TGCTAGCTTTTGTTCgagtcTGGGTGGAACTGCTG). In brief, ZFNs were 
injected into the pronucleus of Sprague-Dawley embryos and ultimately a mutant animal 
was identified with a single-step, whole animal disruption of 39 consecutive base pairs in 








Animals were anesthetized with ketamine/xylazine/acepromazine (77:1.5:1.5 
mg/ml/kg; i.p.) and implanted with an intraoral catheter for tastant delivery, as described 
previously (Wheeler et al., 2008). 26-gauge guide cannulae (Plastics One; Roanoke, VA) 
were stereotaxically placed 2 mm above the nucleus accumbens core (NAc; 
anterior/posterior +1.2 mm from bregma; medial/lateral +2.2 mm from midline; 
dorsal/ventral -4.8 mm from the surface of the skull, at 6° angle) or 3 mm above the 
ventromedial hypothalamic nucleus (VMN; anterior/posterior, −2.5 mm from bregma; 
medial/lateral, ± 0.6 mm from midline; dorsal/ventral, −6.2 mm from surface of the skull) 
and then secured to the surface of the skull using acrylic dental cement (Paxinos & 
Watson, 2007). Animals were given one week to recover prior to experimentation. 
Following the conclusion of the study, brains were collected and analyzed for cannula 
placement using Nissl staining, only those with correct placements were included in the 
studies.  
 
Cholera toxin subunit B microinjections.  
 Animals (n=4) were anesthetized as described above and placed in a stereotaxic 
apparatus. Experimenters then injected 0.5ul of a sterile 10% cholera toxin subunit B 
solution unilaterally into the nucleus accumbens core (AP: +1.5; ML: +2.2; DV:-6.8) 
over a ten minute period. One week after surgery, animals were euthanized, and brains 






Pituitary adenylate cyclase-activating polypeptide (PACAP; n =4-11; 50 
pmol/0.25µl/side in the VMN and 100 pmol/0.5µl/side in the NAc  California Peptide 
Research; Napa, CA), SKF 81297 (1.2ug/0.5µl/side; n=5; Tocris Bioscience; 
Minneapolis, MN), Baclofen + Muscimol (Bac + Musc; n=4; 106.8/5.7 ng/side; Tocris 
Bioscience; Minneapolis, MN) or saline were microinjected over a two-minute period in 
gently restrained awake animals followed by an additional minute to prevent backflow.  
Taste Reactivity.  
 Design 
Following one week to recover from surgery, animals were habituated to the taste 
reactivity chamber for 3 consecutive days for 30 minutes/day. On test day, a 50 mL 
syringe containing a 1% sucrose solution was connected to the animal’s intraoral 
catheter. The syringe was then locked into a syringe pump, which infused the sucrose 
solution at a rate of 1mL/min over a 1 minute trial. Each trial began 15 min following the 
intracranial microinfusion, and appetitive and aversive orofacial responses were video 
recorded using a camera fixed beneath the Plexiglas floor of the testing chamber. 
Animals were given a 48-hour washout period before receiving a second, 
counterbalanced, microinjection of either vehicle or PACAP.   
 Video scoring 
Digital video files of each session were analyzed frame-by-frame over the one-
minute test trial. Scored in 10 second bins, occurrences of lateral tongue protrusions and 




evidence of aversive taste reactivity, as described in previous reports (Wheeler et al., 
2015). After the six 10 second bins are scored frame-by-frame, an animal is assigned  an 
“appetitive responses” and an “aversive responses” score which are the cumulative 
number of appetitive and aversive responses made by that animal over the one minute 
trial. The figures in this chapter reflect the cumulative appetitive and aversive scores.  
Calculating PACAP-induced change in aversive response 
The y-axis on figure 5.2C is reporting within-subject, PACAP-induced changes in 
aversive responses, normalized to vehicle trial aversive responses. To calculate this, we 
used the following equation:  
!𝑡𝑜𝑡𝑎𝑙	𝑎𝑣𝑒𝑟𝑠𝑖𝑣𝑒	𝑟𝑒𝑠𝑝𝑜𝑛𝑒𝑠	𝑜𝑛	𝑃𝐴𝐶𝐴𝑃	𝑡𝑟𝑖𝑎𝑙 ÷𝑡𝑜𝑡𝑎𝑙	𝑎𝑣𝑒𝑟𝑠𝑖𝑣𝑒	𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝑠	𝑜𝑛	𝑣𝑒ℎ𝑖𝑐𝑙𝑒	𝑡𝑟𝑖𝑎𝑙 4 − 1 = 𝑃𝐴𝐶𝐴𝑃	𝑖𝑛𝑑𝑢𝑐𝑒𝑑	D		𝑖𝑛	𝑎𝑣𝑒𝑟𝑠𝑖𝑣𝑒	𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒	 
A result greater than zero indicates that PACAP increased aversive responses, whereas a 
result less than zero would indicate PACAP decreased aversive responses to the sucrose 
solution.   
 
Two meal binge eating design  
Rats were entrained to consume their daily SC intake in a 2-hour period after the 
onset of the dark phase (Meal 1; M1). After establishing consistent feeding patterns and 
weight gain (40-50 kcal/2hr; body weight gain 2-3 grams/day), animals were offered a 
short 15 min meal (Meal 2; M2) of either SC or WD approximately 30 minutes following 




recorded in an additional group of rats that were ad lib fed either SC or WD and 
functioned as additional control groups. 
 
In situ hybridization  
Rat brains were sectioned coronally at 12 µm thickness and then postfixed in 4% 
paraformaldehyde, rinsed in 0.1 M PBS (pH 7.4), equilibrated in 0.1 M triethanolamine 
(pH 8.0), and acetylated in triethanolamine containing 0.25% acetic anhydride. Standard 
in vitro transcription methods were used to generate both sense and antisense riboprobes 
recognizing PAC1R, PACAP, LEPR and BDNF (Choi, Milwaukee, WI) transcripts, 
which were subsequently diluted in hybridization cocktail (Amresco, Solon, OH) with 
tRNA. Sections were hybridized overnight at 60°C with either digoxigenin (DIG) or 
fluorescein (FITC)-labeled riboprobes. After hybridization, slides were treated with 
RNase A and stringently washed in 0.3× SSC at 65°C (PAC1R/BDNF) for 30 min. Slides 
were incubated with an antibody against DIG or FITC conjugated to horseradish 
peroxidase (HRP; Roche) overnight at 4°C. Riboprobe signal was amplified using the 
TSA-Plus fluorophore system with either fluorescein or Cy3 (PerkinElmer; Waltham, 
MA). Image capture was performed using fluorescent microscopy (Axioskop-2; Zeiss, 
Thornwood, NY) and Axiovision image analysis software (Zeiss, Thornwood, NY). 
 
Statistics.  
Using paired t-tests, group differences between hedonic responses to sucrose pre-and 




Software Inc.; San Jose, CA). Additionally, a one-way analysis of variance (ANOVA) 
was used in the experiment involving the two-meal paradigm. Fisher-LSD post hoc test 
was used when a main effect of significance was found.  P values < 0.05 were considered 
statistically significant.  
 
RESULTS 
Ventromedial nucleus of the hypothalamus (VMN) 
The data are presented as cumulative appetitive (lateral tongue protrusion + paw 
licks) and aversive (gapes + paw flails) responses to a sucrose solution following either 
vehicle or PACAP microinjections into the ventromedial nuclei of the hypothalamus 
(VMN).  Within-subject results demonstrated that PACAP microinjected into the VMN 
had no effect on the expression of either appetitive (Fig 5.1A; paired t-test; t= -0.0625; 
DF= 10 p=0.951) or aversive responses to the sucrose solution compared to the vehicle 
trial (Fig 5.1B; paired t-test; t= -1.203; DF=10; p=0.257).  
Nucleus accumbens core (NAc) 
  A separate group of animals were implanted with cannula targeting the NAc as 
well as intraoral catheters and tested in an identical manner. Rats received either PACAP 
or vehicle 15 minutes prior to taste reactivity testing as described above. Interestingly, 
PACAP microinjected into the NAc significantly suppressed appetitive responses (lateral 
tongue protrusions and paw licks combined) to sucrose (Fig 5.2A; paired t-test; t= 3.8; 
DF=9; p=0.004). Although PACAP did not significantly alter aversive responses to 
sucrose (gapes and paw flails combined), compared to vehicle (Fig 5.2B; paired t-test; t= 




the rostral-caudal placement of the microinjection. A Pearson correlation revealed a 
strong rostral-caudal influence of PACAP on the change in expression of aversive taste 
reactivity between vehicle and drug treated groups (r = -0.64, n = 10, p = 0.04; Fig 5.2C).  
Specifically, PACAP microinjected in the caudal NAc (Fig 5.2 bottom; bregma +1.68 to 
+1.32) increased aversive responses to sucrose, while PACAP microinjected into the 
rostral NAc (Fig 5.2 top; bregma +2.02 to +1.92) decreased aversive responses. 
 
 
 In an effort to identify potential PACAP afferents into the accumbens, we injected 
a 10% cholera toxin subunit B solution into the nucleus accumbens and then processed 
the tissue for in situ hybridization (Fig 5.3).  We found that PACAP expressing cells in 
the prefrontal cortex project to the nucleus accumbens core (Fig 5.3C). Furthermore, a  
Figure 5.1 Acute administration of PACAP (50pmol/.25ul) into the 
VMN did not alter hedonic orofacial responses to a 1% sucrose solution. 
(A) A VMN PACAP microinjection 15 minutes prior to a taste reactivity 
test did not significantly alter appetitive responses (lateral tongue 
protrusions & paw licks) to the sucrose solution. (B) A VMN PACAP 
microinjection 15 minutes prior to a taste reactivity test did not 
significantly alter aversive responses (gapes & paw flails) to the sucrose 
solution. Data from each subject are presented, as well as the group 




separate experiment to label PAC1R mRNA’s in the accumbens found that PAC1R was 
densely expressed in this region (Fig 5.4).  
 
 
 To assess if PACAP interacts with dopamine signaling in the accumbens, nucleus 
accumbens cannulated animals entrained to the two-meal binge eating paradigm were 
injected prior to meal 2 with either PACAP, or a D1-like receptor agonist (SKF 81297) 
Figure 5.2 Acute application of PACAP (100pmol/.5ul) into the NAc 
significantly decreased appetitive responses to sucrose and increased aversive 
responses to sucrose in the caudal accumbens. (A) Appetitive responses to 1% 
sucrose were significantly suppressed following a PACAP microinjection. (B) 
PACAP did not significantly alter aversive orofacial responses to sucrose. (C) 
A closer examination of anatomical placements revealed a significant 
correlation between anatomical placement (rostral-caudal) and fold change in 
aversive responses, normalized to vehicle treated aversive responses. (D) 
Representative photomicrographs of coronal (20µm thick) nissl-stained 
sections demonstrating rostral (TOP) and caudal (BOTTOM) NAc cannula 
placements. (E) Representative images adapted from Paxinos & Watson, 2007 
identifying cannula tip placement.  Data from each subject are presented, as 




just prior to the PACAP microinjection (Fig 5.5). Interestingly, we found that animals 
pretreated with the D1 agonist, did not display PACAP-induced hypophagia for a 
palatable food (Fig 5.5; right; P<0.05).   
 
 
With the evidence that PACAP increases system xc- activity and that system xc- 
is heavily implicated in other compulsive behaviors such as addiction (Kong et al., 2016), 
we examined if PACAP-induced decreases in palatable food consumption was dependent 
on system xc- activity (Fig 5.6).  Identical to our previous studies, wildtype animals that 
received a PACAP microinjection prior to meal 2 consumed significantly less palatable 
diet, but system xc- KO rats did not respond to the PACAP microinjection. Interestingly, 
Figure 5.3 PACAP expressing nucleus accumbens core afferents arise from the 
prelimbic cortex. (A) Cannula placement showing where cholera toxin subunit-
B was injected into the accumbens. (B) 10X image of PACAP mRNA 
expression in the prelimbic cortex. (C) 20X image showing co-labeling of 




both wildtype and KO’s displayed similar hypophagic responses to a nucleus accumbens 




With overconsumption as a major contributor to the obesity epidemic (Blundell & 
Cooling, 2000), it is clearly important to investigate the mechanisms by which eating 
beyond satiety is regulated. Previously, we reported that the neuropeptide PACAP acts in 
the rat NAc (but not the VMN) to specifically attenuate palatable food intake in satiated 
rats (Hurley et al., 2016a). To better characterize PACAP-induced voluntary reduction in 
palatable food intake, we used a rodent taste reactivity design to assess if PACAP 
microinjected into the nucleus accumbens (NAc) altered hedonic perceptions of sucrose. 
Figure 5.4 PAC1R mRNA is abundantly expressed in the rat nucleus accumbens 





In the first experiment, we found that PACAP microinjected into the VMN, an 
area where PACAP reduces feeding but does not affect palatable food consumption, had 
no effect on the expression of either positive (appetitive) or negative (aversive) responses 
to a 1% sucrose solution (Fig 5.1). This result was not unexpected since our prior work 
showed that PACAP administered in the VMN only attenuated hunger-driven feeding 
while having no effect on feeding driven by palatability (Hurley et al., 2016a). In 
contrast, administration of PACAP in the NAc significantly blunted appetitive responses 
to sucrose without altering the expression of aversive responses overall (Fig 5.2).  
Figure 5.5 D1 agonist SKF 81297 occludes PACAP-induced hypophagia of palatable 
food in the nucleus accumbens core. (Left) Meal 1 SC intake from the three different 
injection days. (Middle) PACAP and SKF81297 + PACAP did not consume meal 2 
SC differently than control. (Right) PACAP microinjection resulted in a significant 
reduction in western diet intake as compared to the no INJ group and pretreating 




However, a closer examination of the anatomical placements of PACAP delivery 
revealed an additional layer of complexity in the NAc. By examining the behavioral 
responses along a rostral-caudal axis, we found that PACAP delivered to the rostral NAc 
decreased aversive responses to sucrose, while PACAP microinjected into the caudal 
NAc enhanced aversive responses (Fig 5.2C). Taken together, figure 5.1 and 5.2 
emphasize an important point that the PACAP system differentially regulates behavior 
depending on the specific brain region.  
Figure 5.6 Male system xc- KO animals do not 
display PACAP-induced suppresses of hedonic 
hunger following a PACAP microinjection in the 
nucleus accumbens, whereas pharmacological 
inactivation suppresses hedonic hunger in both 




PACAP enhancement of aversive taste reactivity in the caudal NAc is consistent 
with other studies demonstrating a similar NAc rostral-caudal gradient in regulating 
appetitive and aversive behaviors. For example, pharmacological inactivation of the 
caudal medial accumbens shell decreases food intake and appetitive responses to sucrose, 
while also increasing aversive responses (Ho & Berridge; Reynolds & Berridge, 2001).   
In contrast, inactivation of the rostral NAc stimulates feeding behavior and increases 
appetitive responses to sucrose while decreasing aversive responses. 
These results further support our previous findings that bath application of 
PACAP in a slice preparation attenuates evoked activity in medium spiny neurons 
(Hurley et al., 2016a), suggesting that PACAP produces its region-specific effect on taste 
reactivity through inhibitory actions. It is important to recognize that the work identifying 
the rostrocaudal axis in the accumbens targeted the dorsomedial shell, whereas the 
current dataset targeted the area immediately adjacent to this site, in the core of the 
nucleus accumbens. A number of studies demonstrate that the core and the shell 
differentially regulate reward related behaviors (Floresco, McLaughlin, & Haluk, 2008; 
Ghitza, Fabbricatore, Prokopenko, & West, 2004) with a largely non-overlapping efferent 
distribution (Heimer, Zahm, Churchill, Kalivas, & Wohltmann, 1991).  Thus, caution 
must be taken when applying what is known about the shell, to the core. Interestingly, 
emerging evidence demonstrates that the shell-core border, also known as the shore, 
makes connections with the lateral hypothalamus and importantly, these connections are 
not specific to the core or shell, rather they are specific to the dorsomedial component of 




pattern of data is similar to that of the Berridge lab, as both target the same cells in the 
dorsomedial aspect of the nucleus accumbens.  
With our evidence that PACAP expressing cells in the prelimibic cortex project to 
abundant PAC1R expressing cells in the nucleus accumbens (Fig 5.3 and 5.4),  it is 
notable that obese individuals have been reported to display hypoactivity in the prefrontal 
cortex (Small, 2009; van Meer, Charbonnier, & Smeets, 2016). Interestingly, obese 
individuals actively losing weight display enhanced medial prefrontal cortex activity 
when shown a cue for a food reward compared to obese individuals not actively dieting 
(Murdaugh, Cox, Cook, & Weller, 2012). As direct transcranial magnetic stimulation of 
the prefrontal cortex in obese individuals has been shown to decrease food intake and 
increase weight loss (Gluck et al., 2015),  future studies will be necessary to identify the 
specific mechanisms by which prefrontal PACAP projections may regulate hedonic 
hunger in the nucleus accumbens.  
As chemogenetic stimulation of D1-like receptor expressing cells in the 
accumbens increases feeding behavior and inhibition of D1-like receptor expressing 
medium spiny neurons decreases feeding behavior (Zhu et al., 2016), we determined if 
PACAP signaling in the nucleus accumbens interacts with dopaminergic signaling.  
Our findings demonstrate that PACAP-induced hypophagia of palatable food in 
satiated rats is blocked by pretreatment of a D1 agonist (Fig 5.5). Anatomically, the 
pattern of PAC1R expression in the nucleus accumbens is such that it is not present in 
every cell, suggesting maybe it is only on specific subdivision of cells. Future studies are 




In addition to potentially interacting with dopamine, our findings also suggest 
PACAP interacts with the cystine-glutamate antiporter, system xc-. Animals with a 
congenital deletion of system xc- do not display normal PACAP induced hypophagia of 
palatable food intake in satiated rats (Fig 5.6). However, system xc- knock out rats do 
positively respond to pharmacological inactivation using GABA agonists (Fig 5.6) 
suggesting that the circuitry that regulates palatable food consumption remains intact and 
functional. Taken together, PACAP, acting through system xc-, produces a net inhibitory 
effect on MSN’s that regulate the neural encoding of reward.  
Although PACAP regulates caloric deprivation induced feeding in the VMN, 
chapter V demonstrates that PACAP in the VMN does not regulate an animal’s hedonic 
perception of a passively administered sucrose solution (Fig 5.1).  By contrast, PACAP 
administered into highly discrete regions of the nucleus accumbens  does greatly reduce 
the hedonic perception of the sucrose solution (Fig 5.2) illustrating that PACAP 















CHAPTER VI  
 
GENERAL DISCUSSION  
 
Summary  
 The overarching research goal of this dissertation was to assess the mechanisms 
by which the brain regulates feeding elicited by distinct motivations. Specifically, we 
examined the actions of the cystine prodrug, N-acetylcysteine (NAC; chapter II) and the 
neuropeptide pituitary adenylate cyclase activating polypeptide (PACAP) (chapter III-V) 
on differentially motivated feeding. This was achieved by using a variety of preclinical 
rodent feeding paradigms which were designed to elicit feeding of a single motive instead 
of multiple simultaneous motives. The two drives primarily studied in this thesis are 
feeding motivated by food deprivation or homeostatic hunger and feeding elicited by the 
palatability of the food rather than caloric need or hedonic hunger.  
As binge eating disorder is thought to result, in part, through dysregulated hedonic 
hunger, chapter II utilized a well-accepted preclinical model of binge eating to study 
hedonic hunger. We found offering a male rat limited access to a highly palatable food 
adjunct to a nutritionally balance diet drives a compulsive state of rapid consumption, 
which emulates several characteristics of human binge eating disorder (Fig 2.1). As binge 
eating and substance abuse share a number of behavioral similarities (Fig 1.1), these two 
disorders may, in part, develop through similar maladaptive changes to the brain, such 
that one pharmacological intervention may be therapeutic to both disorders. To test this, 
we turn to the cystine pro-drug, N-acetylcysteine (NAC). Although originally used to 




significantly suppresses compulsive behaviors such as obsessive-compulsive disorder, 
trichotillomania and substance abuse. As the effect of NAC on hedonic hunger-stimulated 
feeding had not yet been characterized, chapter II examines the impact systemic and 
central NAC manipulations have on different aspects of feeding behavior. Interestingly, 
systemic and central administration significantly diminishes binge feeding behavior while 
not effecting non-binge relating feeding and did not induce malaise (Fig 2.2, 2.3 & 2.4). 
A potential interpretation of these findings is NAC works centrally to specifically 
regulate feeding elicited by palatability or hedonic hunger, as feeding not specifically 
motivated toward palatability is unaffected by NAC manipulation.   
It is important to note, animals maintained on the preclinical binge eating 
paradigm from chapter II display consistently steady, non-changing values of cumulative 
intake over the duration of the study (Fig 2.1A & Fig 2.3D). This is a result of animals 
increasing intake of the palatable food across experimental days, while also self-limiting 
consumption of the nutritionally balanced diet offered ad lib (Fig 2.1A). Taken together, 
when an animal maintained on this binge paradigm gains limited access to the highly 
palatable food source, the voracious feeding behavior observed is, in part, driven by 
hedonic hunger. However, as animals self-restrict ad lib food intake in anticipation of the 
palatable food to come, it is likely the feeding observed during the binge session may also 
be due to the need to fill caloric stores. Taken together, in chapter III we set out to 
develop a novel rodent binge eating model that would effectively separate homeostatic 
and hedonic hunger within the same animal.  
In chapter III, we first determined 2HR daily access to chow is the optimal 




hunger) and ending in an extreme state of satiety. Animals with 3HR or 4HR access per 
day did not consume more calories than animals with only 2HR access (Fig 3.1B). 
Animals with 6HR per day access to chow, however, did eat significantly more than 
animals only given 2HR access (Fig 3.1B), but closer examination of the meal structure 
during 6 HR access revealed that after animals ate and become satiated they rested and 
then subsequently engaged in a second bout of feeding (Fig 3.1A). Additionally, human 
studies have used 22-HR food deprivation to drive “physical” or homeostatic-hunger 
(Lowe, Friedman, Mattes, Kopyt, & Gayda, 2000). Based on these results, we chose to 
investigate satiated animals (immediately following daily 2HR refeeding) who were then 
offered brief access (15 minutes) to more of the same diet, or the same diet with a novel 
flavor, which did produce any significant alteration of feeding behavior (Fig 3.2B & 
3.2D).  However, animals offered a high fat, highly palatable diet did engage in a large 
second bout of feeding (Fig 3.2A, 3.2B, 3.2D). Unlike the limited access model used in 
chapter II, the two-meal model did not produce any significant reduction in adjunct 
standard chow diet intake in animals expecting the limited palatable diet (Fig 3.2B). This 
results in significant increase in weight gain compared to control animals offered the 
same standard chow diet twice (Fig3.2C).  
Previously, our lab has shown exogenous microinjection of pituitary adenylate 
cyclase-activating polypeptide (PACAP) into the ventromedial nucleus of the 
hypothalamus potently induces hypophagia as well as significant changes in metabolism 
(Resch et al., 2011; Resch et al., 2013; Resch, Maunze, et al., 2014). However, it was still 
unclear if exogenous PACAP injected into the VMN regulates homeostatic hunger, 




paradigm (Fig 3.2) and then cannulated them for the VMN and conducted 
pharmacological manipulation. Interestingly, we found that exogenous PACAP delivered 
into the VMN regulated homeostatic hunger, while not effecting hedonic hunger induced 
feeding (Fig 3.3). Additionally, we found that the behavioral effect of PACAP was 
mimicked by pharmacological activation of cells in the VMN whereas pharmacological 
inactivation produces no significant effect to homeostatic or hedonic motivated feeding 
(Fig 3.3). Taken together, this suggests PACAP in the VMN may lead to the excitation of 
these neurons. Slice electrophysiological experiments conducted by our collaborator Dr. 
Qing-song Liu at the Medical College of Wisconsin confirms that bath application of 
PACAP in slice increases spontaneous firing of VMN neurons (Fig 3.5A). In addition to 
examining PACAP regulation of differentially motivated feeding in the VMN, we also 
targeted the nucleus accumbens in a similarly designed neuropharmacological experiment 
(Fig 3.4). We found exogenous PACAP microinjected into the nucleus accumbens had an 
opposite effect on feeding behavior as it suppressed hedonic hunger without affecting 
homeostatic hunger (Fig 3.4). Interestingly, this effect was mimicked in the accumbens 
by pharmacological inactivation, rather than activation, and confirmed in slice 
electrophysiological studies (Fig 3.5B). Taken together, the significance of the findings in 
chapter III demonstrate that the PACAP system does not just broadly diminish feeding 
behavior as we previously thought. Rather, depending on the site of action, PACAP 
regulates different aspects of feeding behavior through potentially divergent molecular 
mechanisms.  
In chapter IV, we further investigate the mechanisms by which PACAP regulates 




PAC1R signaling blocks central leptin-induced changes to feeding behavior and 
metabolism (Hawke et al., 2009). As it is not known whether this interaction is happening 
at the level of the VMN, in chapter IV we conducted  both behavioral and molecular 
experiments designed to examine this question. We found antagonizing PAC1R signaling 
in the VMN prior to a VMN microinjection of leptin, blocked leptin-induced hypophagia, 
weight loss and changes to core body temperature (Fig 4.1). Using double in situ 
hybridization, we confirmed that PAC1R and the leptin receptor are co-expressed in 
VMN cells (Fig 4.2). In addition to behavioral and anatomical evidence for PACAP and 
leptin interaction in the VMN, we found PACAP microinjected into the VMN increases 
nuclear P-STAT3 accumulation (Fig 4.3A). This is significant because it is well 
documented that activation of the leptin receptor in the VMN drives the JAK2-STAT3 
cascade (Frontini et al., 2008), which also results in the accumulation of nuclear P-
STAT3 in the VMN. Finally, we demonstrated that both PACAP and leptin produce a 
significant increase in brain derived neurotrophic factor (BDNF) and suppressor of 
cytokine signaling 3 (SOCS3) mRNA three hours post VMN microinjection and this 
increase is blocked by pretreatment of PACAP 6-38 (Fig 4.4B). Taken together, PACAP 
regulates feeding in the VMN possibly through a common pathway shared with the 
hormone leptin.  
In an effort to determine if PACAP-regulated feeding was only effective at 
suppressing homeostatic motivated feeding, we microinjected PACAP into the nucleus 
accumbens and surprisingly we found that exogenous PACAP also suppresses 
palatability-driven feeding (chapter III). Chapter V examines in greater detail the 




Interestingly, we demonstrate that PACAP microinjected into the nucleus accumbens 
significantly reduces hedonic drive (Fig 5.2), which is specific to this brain region as 
PACAP microinjected into the VMN had no effect on the hedonic impact of a sweet 
tastant (Fig 5.1). Anatomically, we demonstrate that PAC1R is densely expressed in the 
ventral striatum (Fig 5.4), but not expressed in every cell. In an effort to identify the 
source of PACAP released in the nucleus accumbens, track tracing studies revealed that 
PACAP mRNA is expressed in the prelimbic cortex projects to the nucleus accumbens 
core (Fig 5.3). Additionally, we found pharmacological activation of D1-like receptors or 
global knockout of cysteine glutamate antiporter system xc- sufficient to block PACAP 
induced hypophagia in the accumbens, which suggests the PACAP-accumbens may be 
interact with or be dependent on these two mechanisms.  
 
Why does the limited access model produce anticipatory self-restriction in SC, while 
the two-meal does not?   
 This thesis studied two preclinical rodent models of binge eating disorder: the 
limited access binge model and the two-meal model (Chapter II & III, V).  Both models 
emulate several characteristics observed in human BED, namely a large bout of food 
intake of highly palatable food (Fig 2.1A; Fig 3.2B). The major difference between these 
two paradigms is the accessibility of SC in the limited access model and the restricted 
two-meal model.  Over a 14-day period, animals entrained to the limited access model 
limit ad lib SC intake (which is available continuously), in anticipation of the highly 
palatable diet, which makes up a larger percentage of the daily kilocalorie intake with 
each successive binge session. This results in unchanging cumulative food intake and 




self-restricting behavior indicates that the motivations to consume the highly palatable 
food were both hedonic and homeostatically driven. Interestingly, animals maintained on 
the two-meal paradigm do not display the self-restricting behavior observed in the limited 
access model. This is likely due to the fact that the feeding behavior in the limited access 
model involves motives working simultaneously to regulate feeding behavior, whereas 
the two-meal design temporally separates these drives, resulting in two isolated bouts of 
feeding (Fig 6.1).  
 
 
 An alternative explanation for this difference in self-restricting behavior may be 
the daily food deprivation used in the two-meal paradigm. Food restriction is a useful tool 
to increase motivation in the field of behavioral neuroscience, as it is commonly used to 
facilitate self-administration of a number of drugs of abuse (Carroll, 1985; Carroll, 
France, & Meisch, 1979; de la Garza & Johanson, 1987). Increased motivation associated 
with food deprivation is likely occurring through changes in the mesolimbic signaling. 
Specifically, studies have identified that chronic food restriction decreases dopamine 
Figure 6.1 Diagram of feeding motives in the limited access and two-meal binge eating 




transporter (DAT)-mediated reuptake of dopamine (Zhen, Reith, & Carr, 2006), increases 
DA receptors in the striatum (Lindblom et al., 2006) and increases excitability of 
midbrain dopamine cells (Branch et al., 2013). Although it is possible a hypersensitive 
dopamine system may protect against the self-restriction seen in undeprived animals; it 
should be noted that most of the studies identifying changes in mesolimbic dopamine 
signaling are using animals that are in a chronic negative energy state, whereas the two 
meal model animals are not in a negative energy state (Fig 3.2C). It would be interesting 
to determine if these changes are a result of the chronic negative energy state or cyclic 
food deprivation. Future studies will need to assess if two meal binge animals display 
similar adaptations in the mesolimbic dopamine circuitry.  
 
What is the endogenous role for PACAP mediated signaling in the VMN?    
 To begin to answer this question we first need to first consider the typical feeding 
pattern of an ad lib fed rat. It is well known that Sprague-Dawley rats are nocturnal 
animals and, therefore, eat and are most active during the dark cycle, whereas during the 
light cycle animals eat very little and mostly sleep (Glendinning & Smith, 1994). 
Therefore, if endogenous PACAP released into the VMN acts to induce hypophagia, it is 
unlikely PACAP is being released into the VMN during the dark cycle as the animals are 
actively consuming throughout this period. What is more likely is that PACAP signaling 
in the VMN is important for the maintenance of light cycle feeding behavior as animals 
during the light cycle engage in little to no feeding behavior. In figure 4.1, it is clear that 
blockade of PAC1R dependent signaling in the VMN at the onset of the dark cycle, 




previously published by our laboratory (Resch et al., 2011). In rats microinjected in the 
VMN during the middle of the light cycle with either vehicle, a low, or a high dose of 
PACAP 6-38 there was a significant dose-dependent increase in feeding behavior (Fig 
6.2). Importantly, the high dose is the same dose that produces no significant changes in 
feeding behavior when injected during the dark cycle. This data suggests endogenous  
PAC1R dependent signaling occurs primarily during the light cycle perhaps to inhibit 
feeding during this time period, whereas dark phase receptor blockade had no significant 
effect on feeding because endogenous PACAP signaling may be minimal at this time of 
day (Resch et al., 2011).  
Figure 6.2 Preliminary evidence suggesting PAC1R dependent signaling in the VMN 
crucial for maintaining normal light cycle fasting. (A) VMN cannulated animals (n=5-
7/group/0.25µl/side) injected with PACAP 6-38 consumed significantly more calories than 
vehicle. (B) Cannula placements considered VMN hits. Data presented ± SEM, Tx 




Interestingly, studies have demonstrated in vitro that PACAP, both 1-38 and 1-27 
can be N-terminally truncated to produce PACAP receptor antagonizing metabolites by 
dipeptidyl peptidase IV (Green, Irwin, & Flatt, 2006; L. Zhu et al., 2003). DPP4 
metabolizes PACAP 1-27 at three different sites and administration of DPP4 metabolites 
of PACAP1-27, blocks PACAP induced increase in plasma glucose levels (Green et al., 
2006). An alternative explanation for the pattern of data observed in our light-dark 
PACAP 6-38 data is that PACAP is tonically released, but enzymatically truncated into 
PACAP 6-38 during the dark cycle by DPP4. This is an interesting idea that DPP4 could 
be mediating a PACAP negative feedback loop, however little is known about DPP4 
having action in the brain. 
 
What role does BDNF play in leptin & PACAP regulation of feeding in the VMN?   
 Interestingly, brain derived neurotrophic factor or BDNF mRNA levels in the 
VMN are highly sensitive to energy state, which suggests BDNF action may be important 
for regulating homeostatic hunger related processes (Conner et al., 1997; Xu et al., 2003). 
Further evidence of this is BDNF delivered centrally (Pelleymounter, Cullen, & 
Wellman, 1995), or directly into the VMN display significant suppression in feeding 
behavior (Wang et al., 2010; Wang, Bomberg, Levine, Billington, & Kotz, 2007). 
Furthermore, a global or VMN-specific knockout leads to hyperphagia and increased 
weight gain (Lyons et al., 1999; Mou et al., 2015; Vanderklish & Edelman, 2002). 
Finally, knockdown of BDNF disrupts VMN-leptin induced hypophagia (Lindblom et al., 
2006). With PACAP and leptin both increasing BDNF mRNA (Fig 4.3B) and the 




that PACAP and leptin-induced effects on feeding and metabolism are dependent on 
BDNF as the main effector system. Future studies will need to knockdown BDNF in the 
VMN and microinject PACAP to see if, like leptin, PACAP induced hypophagia is 
impaired.  
 
Why would two peptides (PACAP & leptin) work to produce the same effect? 
 PACAP and leptin manipulations in the ventromedial nucleus of the 
hypothalamus produce a number of similar changes to energy expenditure (Choi et al., 
1999; Dhillon et al., 2006; Jacob et al., 1997; Resch et al., 2011; Resch et al., 2013). 
Chapter IV demonstrates disrupting endogenous PAC1R dependent signaling in the 
VMN is sufficient to block leptin induced behavioral and molecular changes. 
Furthermore, in situ hybridization revealed that both PAC1R and the leptin receptor are 
co-localized in the VMN, which suggests there may be some form of interaction at the 
molecular level. 
 We hypothesize leptin and PACAP signaling in the VMN are not redundant, 
rather each peptide serve a purpose in reporting different aspects of energy status. As 
leptin is secreted peripherally by fat cells and does not vary greatly over days or in 
response to acute caloric intake, leptin serves to report the long-term energy status of the 
organism. Whereas central PACAP may work to report acute energy status as it relates to 
homeostatic hunger. Collectively, the combination of peripheral and central markers of 
energy state increases the complexity by which feeding behavior is regulated in the 




VMN, future studies will have to block the leptin receptor and test if PACAP is still able 
to induce changes in food intake and metabolism.  
  
Frontostriatal PACAP dysregulation in the development of binge eating disorder.  
 
 As PACAP infused into the nucleus accumbens, suppresses palatability driven 
feeding (chapter III) and hedonic drive (chapter V), it is becoming increasingly important 
to identify the relevant PACAP afferents into this region. The nucleus accumbens core 
receives a number of glutamatergic afferents primarily from the prelimbic cortex (PL), 
the basolateral amygdala (BLA) and the ventral subiculum of the hippocampus (Britt et 
al., 2012). In chapter V, we identified PACAP mRNA expressing neurons in the PL 
project to the core (Fig 5.3). As electric stimulation of the PL, decreases binge eating in 
rodents (Sarica et al., 2018), and pharmacological inactivation of the PL specifically 
increases binge eating in rodents (Corwin et al., 2016), the prelimbic cortex appears to be 
a key structure in regulating binge eating.  Interestingly, reinstatement of cocaine seeking 
causes the prelimbic cortex to become active (Kufahl et al., 2009). As neuropeptides are 
typically only released under high frequency stimulation (Smith & Eiden, 2012), we 
hypothesize that motivated behavior towards a natural or unnatural reward will result in 
repeated firing of these prelimbic-core glutamatergic neurons, but after a certain period of 
time, once high frequency stimulation is achieved, we expect PACAP to be co-released 
with glutamate and effectively inhibits the seeking of the reward. Therefore, in BED 
where human and rodent models display significant signs of prefrontal cortex dysfunction 




stimulation is never achieved so therefore, there is no PACAP-induced ‘brake’ on the 
reward consumption. To test this, future studies should stimulate the prelimbic cortex 
following a PACAP 6-38 microinjection into the nucleus accumbens core to determine if 
PL stimulation is still effective at suppressing binge eating in rats.  
 
What is the physiological importance of differentially motivated feeding? 
 In chapter III, we demonstrate the neuropeptide PACAP microinjected in the 
VMN only disrupts feeding elicited by food deprivation (i.e. homeostatic hunger), while 
PACAP microinjected into the same region was ineffective at suppressing feeding driven 
by palatability (hedonic hunger). These results indicate endogenous neuronal activity in 
the VMN, during feeding motivated by food deprivation, is critical for driving this 
behavior as exogenous PACAP application disrupts this specific type of motivated 
feeding. However, when caloric stores have been filled and feeding is motivated by the 
hedonic value of the food rather than the caloric need, we see PACAP, AMPA and 
bacelofen+musicmol manipulations in the VMN do not disrupt hedonic hunger driven 
feeding, suggesting activity in the VMN is not critical for driving this type of hunger.  
 These findings demonstrate the different “motives” we assign as the reasons we 
engage in feeding, are driven in part by unique patterns of neuronal recruitment involving 
different brain regions and signaling systems that govern discrete aspects of feeding 
behavior.  Evolution has shaped the mammalian brain in such a manner that feeding can 
be stimulated and regulated through a number of diverging, complex mechanisms that are 
not purely dependent on energy state. This is physiologically important, because the 




energy dense palatable food insures that the organism continues to survive and propagate 
genetic material. Interestingly, in the nucleus accumbens, we observed PACAP was only 
effective at suppressing feeding driven by hedonic hunger while being ineffective at 
blocking homeostatic hunger. Our results add a layer of complexity to this as we 
demonstrate the PACAP system, which was previously thought to regulate all forms of 




In 2012, a German research group conducted a survey probing subjects to explain 
why they eat what they eat and the research group determined that there were 331 unique 
“motives” people attributed to driving consumption (Renner, Sproesser, Strohbach, & 
Schupp, 2012). Of these motives, the most frequent were caloric driven feeding or 
homeostatic hunger, and palatability driven-feeding or hedonic hunger.  Each motivated 
desire to eat (i.e. hunger) is the culmination of a certain pattern of brain activity that are 
recruited by both internal and external cues (sensory, blood glucose, stomach distension, 
gut-brain peptides, etc.). These motives (i.e. patterns of activation) do not regulate 
feeding in isolation but rather work in concert to guide intake. The complex manner by 
which the brain regulates the nuances of feeding behavior makes it extremely difficult to 
study where disorders in feeding manifest. In an effort to understand how the brain 
differentially regulates these motivated feeding states, the current dissertation employed a 
number of preclinical rodent paradigms (ad lib fed SC, restricted SC, limited access 




that therapeutic approaches to treat substance abuse and other compulsive behaviors, can 
be effective at curbing binge eating as the compulsive aspect of these disorders likely 
manifests through a common route. Additionally, we demonstrated that the neuropeptide 
pituitary adenylate cyclase-activating polypeptide (PACAP) does not regulate feeding in 
the same manner all over the brain, which is highly novel. We observed that PACAP in 
the hypothalamus, suppressed homeostatic hunger by interacting with leptin and BDNF, 
while PACAP microinjected into the striatum, suppresses a fundamentally different 
motivated feeding state (i.e. hedonic hunger) while also impacting hedonic perception. In 
conclusion, the findings presented here shed light on the complexities of the PACAP 
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